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Background and aims: An HIV outbreak among Finnish injecting drug 
users (IDUs) occurred in 1998. By the end of 2005, 282 IDUs were infected, 
most of them by recombinant virus CRF01_AEFin of HIV. After a rapid 
spread, the outbreak subsided, and the prevalence of HIV among IDUs 
remained low (<2%). The purpose of the study was to describe the outbreak 
in order to recognise factors that have influenced the spread and restriction 
of the outbreak, and thus to find tools for HIV prevention. 
Subjects and Methods: Data on IDUs newly diagnosed HIV-positive in 
the Helsinki University Central Hospital area between 1998 and 2005 was 
collected through interviews and patient documents. Study I compared 
markers of disease progression (CD4 cell count and viral load) between 93 
Finnish IDUs and 63 Dutch IDUs representing two seroconverter cohorts 
infected by different subtypes of HIV. In study II, sociodemographic data and 
geographical distribution of 98 Finnish IDUs diagnosed in 1998-2000 was 
compared to data on 47 IDUs diagnosed in 2001-2003, and combined with 
the spatial distribution of employed males. In study III, risk behaviour data 
from interviews of 89 HIV-positive IDUs and 207 HIV-negative IDUs from 
the Riski cohort was linked, and prevalence and risk factors for unprotected 
sex were evaluated. In study IV, data on 238 newly diagnosed IDUs was 
combined with data on Finnish sub-epidemics among men who have sex 
with men (MSM) (n=396) and heterosexuals (n=279) between 1985 and 
2005, and trends and risk factors for late HIV diagnosis (CD4 cell count 
<200/µL, or AIDS within 3 months of HIV diagnosis) were analysed.
Results: Shortly after HIV infection, Finnish IDUs infected with CRF01_
AEFin exhibited higher viral loads than Amsterdam IDUs infected with 
subtype B. Six months after seroconversion the predicted CD4 lymphocyte 
levels did not differ (535 cells/µL and 551 cells/µL, respectively), and there 
was no difference in CD4 development. The Finnish IDU outbreak spread 
and was restricted socially in a very marginalised IDU population and 
geographically in areas characterised by low proportions of employed males 
and low income. Up to 40% of the cases in the two clusters outside city centre 
had no contact with centre, where needle exchange services were available. 
Up to 63% of HIV-positive and 80% of HIV-negative sexually active IDUs 
reported inconsistent condom use within past 6 months. Unprotected sex 
was associated with steady relationships and recent addiction treatment. 
Compared to other transmission groups, HIV-positive IDUs were diagnosed 
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earlier in their infection. During 1998-2001 the median CD4 cell count was 
490 cells/ µL, and only 6% of IDUs were diagnosed late. The sub-epidemics 
among MSM and heterosexuals were also detected relatively early in 1980’s, 
with high median CD4 counts during the four first years of the outbreak 
(575 and 545 cells/µL, respectively) and low proportion of late diagnosed 
cases (13% and 18%, respectively).
Conclusions: The high viral load in early HIV infection may have contributed 
to the rapid spread of recombinant virus in the Finnish outbreak. The 
outbreak was restricted to a marginalised IDU population, and spatially to 
local pockets of poverty. To prevent HIV among IDUs, these pockets should 
be recognised and reached early by outreach work and distribution of needle 
exchange and other prevention activities. To prevent sexual transmission of 
HIV among IDUs, the results suggest that prevention programmes should 
be combined with addiction care services and targeted at every IDU. Among 
Finnish IDUs, early implementation of needle exchange and other preventive 
measures likely played a crucial role in reversing the HIV outbreak.
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ABBREVIATIONS
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HIV has caused one of the world’s worst pandemics that has spread over 
all continents and poses a major challenge to global public health. Where 
heterosexual transmissions in Sub-Saharan Africa are declining first time in 
history, the epidemic among injecting drug users (IDUs) is still expanding, 
especially in Asia and East Europe.1, 2
The spread of HIV among IDUs is a complex issue influenced by 
behavioural, viral, social, political, geographical and economic factors. The 
parenteral transmission of HIV through infected blood is also more efficient 
than the sexual transmission mode.3   In addition, IDUs share other routes of 
HIV transmission: sexual transmissions and indirectly, vertical transmissions 
from mother to child.4, 5 Despite more than 25 years of studies, experience 
and evidence in HIV prevention among IDUs, the epidemic continues. 
In Finland, HIV spread among men who have sex with men (MSM) in 
1980’s and among heterosexuals some years later. In contrast to many other 
Western countries that experienced IDU epidemics already in 1980’s, the 
epidemic among Finnish IDUs spread as late as 1998. Thus, the Finnish 
outbreak is timely and geographically close to the large outbreaks of Eastern 
Europe, but the size of the outbreak remained small and it was limited mainly 
to the Helsinki metropolitan area.6
The rapid spread of the outbreak made it possible to identify seroconverters, 
cases where time of transmission can be estimated based on an earlier HIV-
negative test. Among these cases, it is possible to study the natural history 
of HIV infection in the cohort. The whole epidemic was caused by the 
same recombinant strain CRF01_AEFin, which created a possibility to study 
differences in disease progression between CRF01_AEFin and subtype B 
through international collaboration.7 Helsinki University Central Hospital 
(HUCH) provides services in infectious diseases to about 80% of Finnish 
injecting drug users infected with the recombinant virus. The low threshold 
treatment system made it possible to collect information of majority of HIV-
infected IDUs, and also to reach them for interviews. The data was collected 
from patient documents, and 151 HIV-infected IDUs were interviewed for 
the study.
The purpose of this study was to characterise the IDU outbreak in 
Finland in order to recognise factors that have influenced the spread and the 
restriction of the outbreak. Understanding the backgrounds and dynamics of 
this outbreak may help us to find tools for HIV prevention among IDUs. 
16
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2. REVIEW OF THE LITERATURE
2.1. Epidemiology of HIV 
2.1.1. Global epidemiology of Hiv
The first cases of aquired immunodeficiency syndrome (AIDS) were reported 
from United States (US) in 1981.8 Human immunodeficiency virus (HIV) 
was recognised as the cause of AIDS in 1983, and the HIV antibody test 
became available two years later.9, 10 By that time, HIV had already spread 
widely among men who have sex with men (MSM) and injecting drug 
users (IDUs) throughout Europe and North America.11 However, recent 
phylogenetic analyses suggest that the virus began to spread in Africa more 
than 60 years earlier, near the beginning of the twentieth century.12 In late 
1980’s HIV pandemic had reached all the continents and continued to 
grow.
The global epidemiology of HIV is unequal. The area of Sub-Saharan 
Africa is worstly affected. In many Sub-Saharan countries, HIV epidemics 
are generalised, i.e. self-sustaining in the population, and the prevalence of 
HIV in pregnant women is over 1% nationwide.13 In 8 countries of Southern 
Africa, HIV prevalence exceeds 15%. More than 67% of HIV cases and 75% 
of AIDS deaths occurred in Sub-Saharan Africa in 2007.1 
Most countries in the world have concentrated HIV-1 epidemics, i.e. 
HIV infection is detected in specific groups at risk, including MSM, IDUs, 
sex workers and their regular partners.13 In large populations like South 
and Southeast Asia, the numbers of infected persons are high, even if the 
epidemic in the general population is low. The United States (US) is the 
country most heavily affected of the industrialised nations. In the US, the 
epidemic is concentrated in ethnic minorities and groups at risk, and there 
is a wide geographical variation in HIV prevalence within the country.14 In 
Western Europe, HIV has spread mostly among MSM and IDUs. However, 
heterosexual transmissions have increased, many of them found among 
immigrants.1 During 1997-2002 two thirds of all heterosexually transmitted 
HIV infections diagnosed in Europe were in people from countries with 
generalised HIV epidemics. This reflects the worsening of the HIV epidemic 
in Africa during the 1990s and changing world migration patterns.15
In Finland and in some other European countries the HIV epidemic 
is at low level, i.e. HIV prevalence remains under 5% in any defined 
subpopulations.1,13
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Since 2000, the global percentage of people living with HIV has stabilised. 
The overall number of people living with HIV has increased to 33 millions 
as a result of new infections and beneficial effects of more widely available 
antiretroviral therapy.1 In Sub-Saharan Africa, most national epidemics have 
stabilised or declined. In contrast, the most rapidly expanding epidemics are 
occurring in Central Asia and Eastern Europe.1 In Eastern Europe, where 
severe epidemic emerged among IDUs in the late 1990s, the most affected 
countries are Russia and Ukraine.1, 16 
2.1.2. epidemiology of Hiv among iDus
Recent estimates suggest that 16 million people inject drugs worldwide and 
3 million of these are HIV-positive.17 The largest populations of HIV-positive 
injecting drug users are in Eastern Europe, East and Southeast Asia, and 
Latin America. Of the 148 countries where use of injecting drugs has been 
documented, 128 (86%) countries reported HIV infection among injectors. 
In 2007, countries with largest numbers of injectors were China, the US and 
Russia, where HIV prevalence among injectors was estimated at 12%, 16% 
and 37%, respectively.17 
The geographical distribution of HIV among IDUs varies widely. In Russia, 
the reported prevalence of HIV infection among IDUs in different regions 
varied between 8% and 64%.18 In 2005, the Chinese HIV epidemic among 
IDUs was reportedly concentrated mainly within seven of the country’s 33 
province-level divisions.19 
The development of HIV epidemics among IDUs is diverse as well. Several 
cases indicate that the prevalence of HIV among IDUs exceeded 50% in 
short time.20, 21 The closest example comes from Estonia, where HIV began to 
spread in 2000, resulting in prevalence of 62% among IDUs and the highest 
overall prevalence in Europe (1%).22, 23 There are also cases where after years 
of low and stable HIV prevalence, the prevalence among IDUs suddenly rose 
to 25%.24 On the other hand, a reversed and limited epidemic as the Finnish 
one has been described e.g. in Orrel, Russia.25 Lately, countries with large 
concentrated HIV epidemics among IDUs have reported increased number 
of sexual transmissions.1, 26
2.1.3. molecular epidemiology of Hiv
Subtypes of HIV
HIV entered the human population through cross-species transmission 
from non-human primates in Africa.27-29 The HIV-1 strains M (main), O 
(outlier) and N (non-M, non-O) likely represent different transmission 
events in Central Africa, while HIV-2 originated in West Africa. The major 
HIV pandemic is caused by HIV-1 group M strains, which have caused more 
than 90% of all infections.30 
19
HIV exhibits enormous genetic variability. It evolves within the infected 
person and forms a constantly evolving quasispecies. On the other hand 
HIV evolves between virus strains in different epidemics, which has resulted 
in the development of subtypes.31 Among HIV-1 group M strains, there 
are 9 subtypes (A,B,C,D,F,G,H,J and K).In addition, there are circulating 
recombinant subtypes (CRFs) which are constituted from different subtypes 
and are spreading in populations, and a variety of unique recombinant forms 
(URF) that are identified only from an single individual.31
Six strains dominate the global epidemic. Subtype A is prevalent in 
East Africa and in former Soviet Union, whereas subtype B is widespread 
and dominates epidemics in the Americas, Western Europe and Australia. 
Subtype C accounts for more than 50% of all infections concentrated in 
Southern and Eastern Africa and India. Subtype D circulates in East Africa. 
CRF 01_AE is the main strain throughout Asia, and CRF_AG dominates 
West Africa.30 To date, molecular typing provides an important tool for 
tracking the HIV epidemic, mapping transmission networks and monitoring 
the dynamics of the epidemic.32, 33
Clinical significance of HIV subtypes
Even if there are clear genetic and functional differences between the strains 
of HIV, the clinical implications of subtypes in disease progression and 
transmission has been difficult to define.34-39 The results of clinical studies 
without seroconversion data have yielded conflicting results (Table 1A).40-
48 In contrast, studies among HIV infected individuals with known dates 
of seroconversion have more consistently noticed differences between 
individuals infected with different subtypes (Table 1B).
A study in Senegal of 54 female sex workers reported that seroconverters 
infected with subtype A progressed clinically more slowly than those with 
non-A subtypes.49 In a later cohort from the same study, CRF02_AG-infected 
women had significantly higher mean viral load during the early stage of 
infection than did the women infected with other subtypes.50 In a cohort of 
seroconverters from Uganda, subtype A had lower viral loads and slower 
progression than subtype D.51, 52 Data from a large cohort of seroconverters in 
Thailand suggest that viral loads in early HIV  infection are higher in those 
IDUs infected with CRF01_AEFin than in IDUs infected with subtype B but 
showed no difference in progression.53 Ethiopian seroconverters infected 
with subtype C had lower viral loads in the first months after seroconversion 
than did Dutch seroconverters with subtype B.54
Despite the trend that seroconversion studies have found differences in 
viral loads or disease progression, all studies have their limitations. Most 
studies include small number of cases, short follow-up, different cohorts, 
and sometimes many subtypes grouped together (for example “non-A” 
subtype). The endpoints of the studies differ, and some studies lack viral 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































difficult due to differences in the seroconversion intervals. Furthermore, 
subtypes often cluster within risk and ethnic groups, and host genetics as 
well as co-infections may confound the results. Finally, subtype-related 
differences exist in the viral load assays.55, 56 
Even if it is theoretically possible that novel subtypes with resistance 
properties could begin to circulate, there is so far no evidence that response 
to combination antiretroviral therapy (cART) would differ between the 
subtypes of HIV.57-60 For vaccine development, the HIV diversity reflected 
in development of subtypes, is huge challenge.61
2.1.4. epidemiology of late Hiv diagnosis
Diagnosis of HIV and AIDS
Diagnosis of infection with HIV can be made by several different kinds 
of laboratory assays, in most cases by demonstrating the presence of HIV 
antibodies in the blood.62 Antibodies against HIV usually become detectable 
6-8 weeks after infection; by 12 weeks, nearly all infected individuals are HIV 
antibody-positive.62, 63 The new generation of assays also incorporates HIV 
antigen detection, which shortens the window period with approximately 
one week.64 
Diagnosis of AIDS is based on diagnosing one or more indicator diseases 
(AIDS-defining conditions, Table 2) in an HIV-infected individual.65 In the 
US, the surveillance definition of AIDS also includes all HIV cases with CD4 
cell counts of fewer than 200/µL, whereas the European definition is based 
only on the typical illnesses.65, 66 
The reporting of newly diagnosed HIV and AIDS cases varies. To date, 
most industrialised countries report all newly diagnosed HIV infections as 
well as AIDS cases, whereas some countries still report only AIDS cases.67 
In resource-restricted settings where no HIV or AIDS case reporting exists, 
repeat prevalence surveys have served to monitor the HIV epidemic.68
Newly diagnosed HIV cases may have been transmitted recently or for 
years earlier. In HIV surveillance data, the incidence rates of newly diagnosed 
HIV cases not only reflect new transmissions, but also include individuals 
infected years before undergoing HIV testing.69 The delay between the 
transmission and diagnosis of HIV can be roughly estimated using the 
CD4 count measured closest to the time of the HIV diagnosis. Since the 
CD4 cell count decreases over time after HIV infection, high CD4 counts 
suggest recent transmission, whereas lower counts most likely reflect old 
transmissions.70 
During the past ten years, serological tests have been developed that 
recognise newly transmitted HIV infections (Serological Testing Algorithms 
for Recent HIV Seroconversion, STARHS).71 These tests can recognise recent 
infections (seroconversion within 6 months), and have served to estimate 
the proportion of newly acquired infections in different populations. The 
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experiences of countries such as France and Germany suggest that despite 
their limitations, these tests seem helpful in HIV surveillance and in 
estimating the true incidence of HIV.72-74  
Table 2. 1993 European AIDS surveillance case definition, list of indicator diseases.66
Bacterial infections, multiple or recur-
rent in a child under 13 years of age




Coccidioidomycosis, disseminated or 
extrapulmonary
Cryptococcosis, extrapulmonary
Cyptosporidiosis, intestinal with diar-
rhea (duration >1 month)
Cytomegalovirus disease, other than 
liver, spleen, or nodes in a patient over 
one month of age
Cytomegalovirus retinitis (with loss of 
vision)
Encephalopathy, HIV-related
Herpes simplex: chronic ulcer(s) (dura-
tion >1 month) or bronchitis, pneu-
monitis, or oesophagitis in a patient 
over one month of age
Histoplasmosis, disseminated or extra-
pulmonary
Isosporiasis, intestinal with diarrhea 
(duration >1 month) 
Kaposi’s sarcoma
Lymphoid interstitial pneumonia in a 
child under 13 years of age
Lymphoma, Burkitt’s (or equivalent)
Lymphoma, immunoblastic (or equiva-
lent)
Lymphoma, primary, of the brain
Mycobacterium avium complex or M. 
kansasii, disseminated or extrapulmo-
nary
Mycobacterium tuberculosis, pulmo-




Mycobacterium, other or unidentified 






Salmonella (non-typhoid) septicaemia, 
recurrent
Toxoplasmosis of brain in a patient over 
one month of age
Wasting syndrome due to HIV
Prevalence of late HIV diagnosis
In the era of cART, early diagnosis of HIV infection is essential to prevention, 
control and care. Delayed HIV diagnosis appears to be associated with 10-fold 
higher short-term mortality and at least 2-fold short-term costs.75-78 Despite 
earlier initiation of cART, mortality is higher than for those diagnosed 
earlier.79 Furthermore, the consequences and costs of late HIV diagnosis are 
multiplied at the epidemiological level: individuals unaware of their HIV 
infection for years may be a major source of new infections and thus could 
represent the driving force of the epidemic.80-82 
During the past decade, epidemiology of late HIV diagnosis has become 
an important issue, and increasing number of studies and reviews have been 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































diverse (late presenters, late testers, late diagnosis), as are the definitions. 
Most often late diagnosed person (i.e. late presenter) is defined as a HIV case 
diagnosed with CD4 count below 200 cells/µL, or with an AIDS defining 
illness at HIV diagnosis 
Broadly, two kinds of studies exist. Most recent studies include all newly 
diagnosed HIV cases in the defined area and use this number as denominator 
to calculate the proportion and study determinants of late HIV diagnosis 
(Table 3). There are also studies that use AIDS cases as denominator (i.e. 
report the proportion and determinants of late-diagnosed cases of all 
AIDS cases). The latter studies show illustratively that in the era of cART, 
late diagnosis explains an increasing proportion of AIDS cases and AIDS 
deaths in Western countries.113-115 However, the studies that include AIDS 
cases as denominator cannot be directly compared to those that include all 
newly diagnosed HIV cases, since the interpretation of the results differs 
considerably. 
Prevalence of late diagnosis varies between 20% and 51%. In Europe, 
the proportion of late-diagnosed cases is often between 30% and 45%. The 
percentages of late-diagnosed cases are naturally higher in those studies that 
use the definition “diagnosed with CD4 count<200 or AIDS”, and lowest 
in those few studies that use the definitions “CD4 cell count <50/µL”, or 
“diagnosed with AIDS”. Universal definitions and monitoring of CD4 count 
at HIV diagnosis are warranted.116 Late diagnosis tends to be even more 
prevalent in United States, and especially in developing countries, from 
where only few studies originate.117-119 Published studies from Eastern Europe 
are not available. Interestingly, the few studies that include cases before and 
after introduction of cART have recorded no decrease in late HIV diagnosis 
between these periods.75, 90, 102 
Risk factors for late diagnosis
In most previously published studies, cases diagnosed late were likely to 
be older, black or non-native, and not tested for HIV previously.75, 76, 88, 90, 
91, 102 In Australia, partners of individuals who came from high prevalence 
countries were at risk for late diagnosis.83 In general, low perceived risk for 
HIV infection is a risk factor for late HIV diagnosis. Among non-migrant 
heterosexual population in France, late diagnosis was more frequent among 
longstanding couples and couples with children. Conversely, late diagnosis 
was less likely among individuals with large number of sexual partners.88, 120 
In some studies, living in a region with a low prevalence of HIV was a risk 
factor for late diagnosis.75, 121, 122
In many studies from Europe, MSM are diagnosed earlier than other 
transmission categories.79, 96, 98, 100Also IDUs often test positive early in their 
infection, but contrary results are also reported (Table 3). 76, 91, 101 Moreover, 
many studies omit IDUs or the number of IDUs is small. 
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An Italian study showed that risk factors for late diagnosis are different 
from risk factors for late entry to HIV care.91 IDUs were diagnosed earlier 
than other transmission risk groups, but IDU was a risk factor for delayed 
entry to care (56% of Italian IDUs delayed more than 6 months). In addition 
to IDUs, delayed entry to care was more common among those, who were 
not tested for HIV before, unemployed, and had received no HIV counselling 
after HIV test.91 In an earlier study from Canada (1999), longer delays were 
reported among young, male and MSM cases.123
Strategies to encourage earlier HIV testing
To facilitate early HIV diagnosis, new HIV testing policies have been 
promoted. In 2006, CDC recommended routine HIV screening in all health 
care settings for patients aged 13-64 years, unless the local HIV prevalence 
is known to be less than 0.1%.124. New HIV testing guidelines are also 
considered in Europe, and the cost-effectiveness of increased or routine 
HIV testing in health care settings is discussed.82 In the UK, new guidelines 
for HIV testing recommend HIV testing in a wider range of settings than 
is currently the case, and lists specific indicator conditions, where HIV test 
should be routinely recommended.125
2.1.5. Hiv in finland
HIV surveillance in Finland 
HIV infection is a notifiable disease in Finland, reported by the diagnosing 
laboratories and physicians in each case. Reporting and case linking are tied 
to each individual’s unique identity codes.6 The European case definition 
for HIV and AIDS is used.65 The National Institute for Health and Welfare 
maintains the National Infectious Disease Register (NIDR) for surveillance 
purposes.126 The system records major transmission groups and has been in 
use without major changes since the mid-1980s.6 In 2006, baseline CD4 cell 
count was added to the notification form filled by the reporting physician.
Blood and organ donations are universally screened for HIV in Finland. 
Also, pregnant women are offered HIV testing since 1997, and over 99% 
accept testing. Voluntary and free HIV testing is available in health centres 
throughout the country. In addition, HIV testing is offered in biggest cities 
at STD (sexually transmitted disease) clinics, NGO (non-governmental 
organisations) AIDS support centres, and within needle exchange programs 
for IDUs. Voluntary targeted unlinked- anonymous studies have served 
as additional data sources to address prevalence among MSM and IDUs.6 
Outside blood donor screening, approximately 150 000 HIV tests are 
performed every year with no significant changes in the number of tests 
over years (Department of Infectious Diseases Surveillance and Control, 
National Institute for Health and Welfare).
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Epidemiology of HIV in Finland
Finland is a country with low prevalence of HIV (adult HIV prevalence 
<0.1%).126 By the end of 2008, cumulatively 2410 HIV cases had been 
reported. Of these 520 developed AIDS including 285 who had died of 
AIDS.126 Aft er introduction of cART in 1996, AIDS cases declined until 
2000, when a new increase was observed. Most of these AIDS cases are 
diagnosed close to HIV diagnosis, and may thus refl ect the problem of 
delayed HIV diagnosis.6
In 1980’s, HIV was transmitted among MSM, and the numbers 
of heterosexually transmitted cases were small. Toward 1990’s, more 
heterosexually transmitted cases emerged. From the beginning of 1990’s 
the incidence was relatively stable in both sexual transmission groups until 
the peak years 2006 and 2007 (Figure 1). Th e annual incidence rates of HIV 
in Finland (35 cases/million population) had in 2007 risen close to that 
of other Nordic countries (47-56/million), still being lower than in most 
Western European countries (50-100/million).1, 6 
Figure 1. Newly diagnosed HIV cases in Finland among men who have sex with 
men (MSM), injecting drug users (IDUs) and heterosexual transmissions (National 
Infectious Disease Register, National Institute for Welfare and Health).
Of the heterosexual cases, 59% occurred among Finnish citizens, with 
a similar increase in both migrant and domestic cases. In addition, of 
cases among Finnish citizens, 38% have reportedly been travel-associated. 
Th us, only a minority of heterosexually transmitted cases refl ect changes 
in the domestic epidemic. In contrast, Finnish citizens account for 89% of 
transmissions in the MSM group, in which one study has estimated the HIV 
prevalence to be 4.5% in 2006.6
In contrast to many other Western European countries, HIV outbreak 
among Finnish IDUs occurred as late as 1998. Th e number of new HIV 
infections among IDUs increased rapidly until 2000, when it began to 
decline. Between 1998 and 2008, 338 IDU cases were reported, over 80% 
of them from the Helsinki metropolitan area. Th e majority of infected IDUs 
(88%) were Finnish citizens.6, 126 
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Nearly all IDUs were infected with a recombinant subtype AE (CRF01_
AEFin) of HIV, whereas only subtype B was found among the 28 single HIV 
cases detected among IDUs between 1983 and 1997.7 Until the Finnish 
outbreak, CRF01_AE had been prevalent in the Far East but not in Western 
countries.127
The shape of the Finnish incidence curve in IDU epidemic is similar to 
many other IDU epidemics in 1990’s, but the HIV prevalence among IDUs 
remained low. Between the years 1999 and 2003 more than 7000 samples 
from needle exchange programs (NEPs) and prisons were tested with a rapid 
HIV test (voluntary diagnostic test).128 During the testing period the HIV 
antibody prevalence decreased from 6.7% to 0.4% in NEPs and from 2.4% to 
0.3% among prison inmates with unknown serostatus. Based on prevalence 
surveys, the HIV prevalence among IDUs in the Helsinki metropolitan area 
was estimated at 1.2 % in 2007.129 
Only 14 mother-to-child transmissions have been reported to the National 
Infectious Diseases Register, all but one of which occurred prior to arrival 
to Finland. Since 1985, no cases of HIV infection due to domestic blood 
transfusions or blood products have been reported in Finland.6
2.2. Factors influencing the spread of HIV among IDUs
2.2.1. injecting behaviour
Injecting as a risk factor for HIV infection
Injecting behaviour that leads to HIV transmission has been studied since 
early in the epidemic.4, 130 Sharing of needles and syringes was identified as a 
major route of HIV transmission among IDUs and became the primary focus 
of HIV prevention programmes in this population.4, 131 In addition to needles 
and syringes, sharing drug paraphernalia (cooker, cotton and rinse water) 
was identified as a likely mode of HIV transmission.132 Similarly, the HIV 
risk among IDUs in later epidemics in Thailand and Russia correlate with 
sharing needles and other equipment, and frequency of injection.133, 134
There are also differences in HIV risk factors between the studies and 
geographic areas, which reflects variation in risk behaviours, social context 
of risk behaviour, cultural differences, and differences in HIV prevalence.135 
In early epidemics in the US, HIV transmissions were associated with the use 
of “shooting galleries”, unofficial locations where IDUs could rent or borrow 
needles and syringes and where the injection equipment was often used 
repeatedly and may have contained contaminated blood.136 Correspondingly, 
some countries report a history of having injected drugs in prison the 
strongest predictor of HIV infection among IDUs.137, 138
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Risk factors for sharing
Sharing of injection equipment is the most common measure to describe 
risky injection behaviour. Numerous studies have examined the determinants 
of sharing injection equipment. The type and frequency of drug use, multiple 
needle use, severity of drug addiction, unstable living, history of arrest, recent 
involvement in crime, and lower socioeconomic status have been found 
to associate with sharing injection equipment.139-143Also, sharing is more 
common among IDUs with multiple injection partners and among those 
who live or have sex with injection partners.142, 144, 145 In sociological studies, 
many characteristics of social networks correlate with sharing injection 
equipment.146
Many attitudes: fear of police, low levels of perceived risk of infection 
with HIV, lack of knowledge of HIV transmission, and peer influences, 
influence the risk of sharing.139, 144, 145 Furthermore, irregular use of NEP 
services and lack of exposure to AIDS interventions have been shown to 
be risk factors for sharing.139, 147 In contrast, treatment contact with general 
practitioners has been associated with decreased risk for sharing injection 
equipment.142, 148 
Most studies report lower prevalence of sharing among HIV-positive than 
among HIV-negative IDUs. In the Netherlands, the risk factors for sharing 
were largely the same among HIV-negative and HIV-positive participants.147 
Among HIV-positive active IDUs recruited to a secondary prevention 
intervention programme, admission to a hospital for drug treatment in 
the past 6 months, injecting with more than 1 person in the past 3 months, 
and having depressive symptoms were positively associated with lending 
syringes.149 In a longitudinal analysis of the same study, about half of active 
injectors reported at least one sharing episode within past 6 months. Higher 
levels of psychological distress were associated with a greater likelihood of 
drug paraphernalia sharing.148
2.2.2. sexual behaviour
Risk for sexual HIV transmissions among IDUs 
Unprotected sex is a well-known risk factor for HIV among IDUs.4, 150 
However, sexual HIV risks have received less attention among prevention 
programmes targeted at IDUs.151
Where prevention programmes have successfully reduced injection-
related risk behaviours, unprotected sex has become a major risk factor 
for new HIV infections among IDUs, especially in mature epidemics. A 
19-year prospective cohort study of drug users in Amsterdam identified a 
decline in HIV incidence and injecting, but not in unprotected sex. New 
seroconversions since 1996 were related to having a heterosexual contact.152 
In a case control study from San Francisco, risk for HIV seroconversion was 
higher among MSM and young female IDUs, as well as female IDUs who 
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reported having traded sex for money. Thus, all the main risk factors for 
HIV transmission among IDUs in that study were sexual.153 
Many studies have found the risk for sexual HIV transmissions to be 
high especially among female IDUs. In a study from Vancouver, HIV-
positive sex partner was strongly and independently associated with HIV 
seroconversion, especially among women.154 Similar results were obtained 
from 5 European cities: among IDU women the strongest risk factor for HIV 
infection was HIV-positive steady partner. In addition, commercial sex and 
newly diagnosed STIs were risk factors for HIV infection.155Among female 
IDUs in Baltimore, HIV incidence was twice as high among those who had 
recently had sex with an IDU.156
Risk factors for inconsistent condom use
The commonly used measure to describe the prevalence of unprotected sex is 
inconsistent condom use. Some studies measure inversely consistent condom 
use or indirect measures as STDs.131 The prevalence of inconsistent condom 
use among western IDU populations varies between 40% and 70%.152, 157-161 
Inconsistent condom use has been found to be more common with main 
partners, when being high on drugs while having sex, and when believing 
that condom use will decrease pleasure.162 In some studies, stimulant users, 
including crack smokers, have been found to engage in high-risk sexual 
behaviour, often while high on drugs.162-164 Likewise, unprotected sex is 
associated with high alcohol consumption, especially among female IDUs.157, 
165 In contrast, the use of condoms has been associated with HIV positivity, 
having a casual sex partner, greater personal acceptance of condoms, and 
greater partner receptivity.166-168 
2.2.3. role of Hiv prevention interventions                                                                 
Needle exchange programmes (NEPs)
Evidence strongly suggests that NEPs are effective in HIV prevention among 
IDUs. An ecological study compared the HIV prevalence of IDUs in cities 
without NEPs to that of cities with NEPs. In the 52 cities without NEPs, HIV 
prevalence increased by 5.9% per year, whereas HIV prevalence decreased 
by 5.8% per year in the 29 cities with NEPs.169
NEPs are associated with reduced HIV incidence. Des Jarlais et al. have 
reported a 70% reduction in HIV incidence associated with NEP attendance 
in New York.170 Many behavioural studies have  shown significant reductions 
in needle sharing associated with NEP use.147, 150, 171, 172 Two recent reviews 
summarise the existing evidence that NEPs are effective in reducing HIV and 
are unassociated with serious negative consequences, including increasing 
illicit drug use.173, 174
Even if condoms are provided in most NEPs, only a few studies have 
examined the effects of NEP use on risky sexual behaviour, and the findings 
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are inconsistent.175 Some recent studies have reported a significant increase 
in condom use with the main partners of NEP users.176, 177
Among a large number of studies that show the benefits of NEPs, only 
a few studies have shown negative effects. In two studies from Canada, 
use of NEPs was associated with HIV positivity, possibly because of their 
appeal to high-risk IDUs. However, these studies have also been used to 
show that changing needles and syringes alone is insufficient: NEPs should 
be combined with comprehensive programmes that include counselling, 
support and education.178, 179 To date, most NEPs provide HIV counselling 
and testing, condoms, HIV prevention education, and referrals to addiction 
treatment. In addition, some include STD screening and primary health 
care services.180, 181 
Extensions of NEPs have also arisen in the form of medically supervised 
injecting centres. At these centres, IDUs can access sterile injecting equipment, 
inject pre-obtained illicit drugs under the supervision of nurses, and receive 
nursing care and addiction counselling.182, 183 In Canada, these medically 
supervised safer injection facilities (SIFs) were introduced as a response to 
continuing HIV and overdose epidemics among IDUs, and have been shown 
to reduce needle sharing and unprotected sex.161, 183
Outreach
Outreach strategies aim to deliver information and services to IDU 
populations and to establish links between IDUs and health services. Of 
various models of outreach programmes, many are based on peers who 
deliver HIV prevention services targeting IDU social networks in community 
settings.184 Outreach has been identified as one of three common prevention 
strategies contributing to low seroprevalence levels in cities where HIV 
has entered the IDU population.185 The other two components were easy 
access to clean needles and syringes and rapid implementation of prevention 
activities. 
One of the first studies to examine outreach programmes in relation 
to new HIV infections showed a decline in HIV incidence from 8.4 to 2.4 
per 100 person-years. High-risk drug use behaviour declined from 100% 
to 14% compared to 50% among IDUs not in the outreach programme.186 
Numerous subsequent studies have shown outreach progammes to be 
an especially effective strategy for reaching out-of-treatment IDUs.184 A 
significant proportion of IDUs exposed to outreach programmes change their 
behaviour, a trend associated with lower rates of new HIV infections.184
Opiate substitution treatment
Opiate substitution treatment have been shown to reduce the spread of HIV 
by reducing injecting drug use and sharing of injection equipment.187-189 
Most studies are conducted in Methadone Maintenance Treatment (MMT) 
programmes, but buprenorphine treatment has proved equally effective.190 
33
Opiate substitution treatment also supports adherence to antiretroviral 
therapy and helps IDUs to achieve treatment results similar to those of other 
groups.191 However, the lack of effective substitution treatment for stimulant 
injectors is a major problem in countries where stimulant use is common.192 
Furthermore, there is less definitive evidence that MMT prevents risky sexual 
behaviour.187, 188 Even with reductions in the proportion of multiple sex 
partners or exchanges of sex for drugs and money, substitution treatments 
have had only limited effects on condom use.188
Behavioural interventions targeted at sexual behaviour
Where most HIV prevention interventions have been shown to decrease 
risky injection-related behaviour, many studies over the years have shown 
that these same interventions have little or no effect on sexual behaviour.187, 
193 However, a meta-analysis of 37 randomised controlled trials suggest that 
behavioural interventions are effective in reducing HIV risk behaviour 
among IDUs, including unprotected sex. The studies included group or 
individual interventions that provide an average of eight sessions for a one-
month course targeted at both out-of-treatment IDUs and IDUs enrolled 
in outpatient or inpatient substance abuse treatment programmes.194 
Behavioural interventions were effective in reducing injecting-related and 
sexual risk-related outcomes as long as they targeted both high-risk drug and 
high-risk sexual behaviours, and included certain components that address 
behavioural skills. The effect of the interventions on condom use tended to 
diminish over time, which suggests the need for “booster sessions” or other 
additional strategies to maintain the initial effect.
HIV counselling and testing
HIV positivity has been shown to increase condom use among IDUs. In a 
prospective cohort study in Thailand, those IDUs who seroconverted during 
the study began to use condoms more consistently.195 Despite the same serial 
interventions, HIV-negative IDUs failed to change their behaviour. 
The same phenomenon has been described regarding injecting-related 
risks, and has been called “informed altruism” by des Jarlais et al.196 In 
their study in New York, HIV-positive participants reduced their lending 
of needles and syringes (distributive sharing) more than did HIV-negative 
participants, but no differences occurred in borrowing (receptive sharing).196 
Several cohort studies and trend analyses indicate that many IDUs reduced 
their needle and syringe sharing after the HIV epidemic.147, 197-200 However, it 
is difficult to distinguish the isolated impact of HIV diagnosis, counselling 
and testing from that of simultaneous prevention efforts. Furthermore, 
participating in studies may also serve as an intervention.200
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Combination of different prevention efforts
It is well recognised that increased HIV testing, or providing only clean 
needles and syringes without other preventive measures, cannot prevent 
HIV epidemics among IDUs.24 The term “harm reduction” is often used 
in association with NEP and opiate substitution treatment, and essentially 
means that reducing the adverse consequences of drug use is considered 
even more important than reducing illicit drug consumption.201 The “harm 
reduction packages” introduced by the World Health Organization (WHO), 
however, include a much wider range of prevention components from needle 
and syringe programmes to antiretroviral therapy for HIV-positive IDUs 
(Table 4).202 Such preventive efforts are linked to each other: NEPs offer 
condoms, HIV testing and referrals to addiction treatment, which again may 
include HIV testing, behavioural interventions, and other efforts. 
Table 4. Comprehensive harm reduction package for injecting drug users (WHO 
2009).
Needle and syringe programmes (NSP)
Opioid Substitution Therapy (OST)
Voluntary HIV Counselling and Testing (VCT)
Antiretroviral Therapy (ART)
Sexually Transmitted Infections (STI) prevention and condom programmes for 
IDUs and partners
Information, Education and Communication (IEC) for IDUs and their sexual part-
ners through Outreach
Hepatitis diagnosis, treatment and vaccination (where applicable)
Tuberculosis (TB) prevention, diagnosis and treatment
Coverage
To prevent HIV among IDUs, interventions must reach adequate numbers 
of IDUs. Estimates indicate that only 5% of IDUs in the world currently have 
access to HIV prevention services.203 The term “coverage” is used to describe 
the proportion of IDUs in the reach of effective intervention.204 
A recent multi-method study investigating access to needles and syringes 
in three Russian cities indicates that fewer than 7% of IDUs have ever had 
contact with NEPs, as the vast majority used pharmacies to access injecting 
equipment.205 In Pakistan, where HIV prevalence among IDUs has been 
rising since 2003, 32% of IDUs in the area of specific programmes, but 
only 17% of IDUs nationwide, reported ever having used harm reduction 
services.206 
Syringe coverage for heroin injection was studied in 35 large metropolitan 
areas in the USA. Only 3 syringes were distributed per 100 injection events. 
Thus, only a small fraction of IDUs appeared to have contact with an NEP, and 
access varied greatly depending on where the IDUs lived.207 Syringe coverage 
improved the longer the NEP was in operation. Moreover, government 
funding for NEPs contributed to successful NEP coverage.207 
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As these studies show, definitions of coverage vary between studies, and 
there are problems in measuring and defining acceptable levels of coverage 
for different intervention types. Including pharmacies and secondary syringe 
exchange as safe needle sources, and defining the size of the hidden IDU 
population (as a denominator of coverage) are only a few of the many 
challenges for the studies.208 Nevertheless, the studies show that low coverage 
may explain the failures of harm reduction programmes in many areas. 
Recently, UNAIDS (Joint United Nations Programme on HIV/AIDS) and 
the WHO have published recommendations for “high coverage sites”, based 
on case studies from seven cities in developing and transitional countries. 
The report lists common features of these successful programmes where 
more than 50% of IDUs had been reached by one or more HIV prevention 
programmes.209 The report concludes that the most significant finding is 
that high level coverage can be attained, also in developing as well as in 
transitional countries. 
Even if effective risk reduction among IDUs has been achieved, no studies 
have reported the complete elimination of high-risk behaviour. Among 
active IDUs in the Amsterdam Cohort Study, the proportion of those who 
reported lending injection equipment dropped below 10% in five years 
among HIV-negative IDUs, and below 5% among HIV-positive IDUs, and 
borrowing dropped below 20% and 10%, respectively.147 
2.2.4. Hiv viral load
Viral load as risk factor for transmission 
HIV transmission risk is strongly associated with HIV viral load, which 
is well documented in sexual transmissions and in mother-to-child 
transmissions.210-214 The HIV viral load – and thus the transmission risk – is 
highest in the early stages of the infection.215 In a study among serodiscordant 
heterosexual couples, the infectiousness was 26 times higher during the 
primary infection than during the asymptomatic phase of the infection, 
and 7 times higher in the late-stage infections.215 Even small changes in the 
HIV viral load may influence the probability of transmission. The likelihood 
of transmitting HIV by heterosexual contact increases by 20% with every 
0.3 log10 increment in the HIV viral load, 40% with a 0.5 log10 increment, 
and 100% with a 1.0 log10 increment in the HIV viral load, respectively.216 
Whether these studies can directly be generalised to the IDU population 
remains unclear. However, since the main transmission mode among IDUs 
is parenteral, the plasma viral load could be expected to correlate with the 
transmission risk even more strongly than in heterosexual transmissions, 
in which HIV RNA in seminal fluid or vaginal secretion may differ from 
the HIV RNA measured in plasma.217, 218
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Impact of HIV treatment
Since cART suppresses the viral load, the initiation of effective cART is 
followed by a reduction in the probability of transmission. This effect 
has been shown in mother-to-child transmissions and among discordant 
heterosexual couples.219, 220 Similarly, a study among MSM in San Francisco 
showed a 60% decrease in infectivity after the widespread use of cART 
despite the increase in unprotected sex.221
In addition, ecological evidence suggests that ART can reduce transmission 
risk. Providing free cART to all HIV-infected citizens was associated with 
a 53% decrease in the estimated HIV transmission rate and contributed to 
the control of the HIV epidemic in Taiwan.222 A recent congress report from 
Canada indicates that cART is also effective in preventing new transmissions 
among IDUs.223 Community plasma levels among HIV-positive IDUs 
correlated with the community HIV incidence rate and strongly predicted 
HIV incidence independent of unsafe sexual behaviour and the borrowing 
of used syringes.223 
Based on mathematical models, some researchers have suggested that 
universal voluntary HIV testing and immediate start of ART, combined with 
present prevention approaches, could profoundly impact severe generalised 
HIV epidemics.224 Another modelling study from Canada studied the 
potential impact of expanded cART coverage on an HIV epidemic. The 
results indicate that the expanded and early administration of cART lead 
to substantial reductions in the growth of the HIV epidemic and in related 
costs.225 
2.2.5. spatial spread of Hiv among iDus
Spatial differences in HIV risk among IDUs
The geographical distribution of IDUs, HIV infected IDUs, and risk 
behaviour varies not only at country or city level, but also within cities and 
communities, which reflects and also creates different “risk environments” 
in relation to HIV risk.226, 227 
One study from Vancouver evaluated neighbourhood ecological factors 
associated with drug use and HIV risk. The results indicated that geographical 
place of residence was independently associated with HIV infection among 
IDUs, even after adjusting for risky injecting behaviour.228 
A study from St. Petersburg examined the spatial distribution of IDUs, of 
whom 30% were seropositive. The study combined the spatial distribution of 
HIV, sociodemographic data, and behavioural data on the study population. 
HIV-infected individuals were tightly clustered, and co-clustered with a high 
frequency of heroin injection, receptive syringe sharing, being under the 
age of 24, and living with parents. During the one-year follow-up period 
beginning in 2002, 20 new seroconversions occurred, of which more than 
half were located within or adjacent to the clusters.229
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Geographical data have also been combined with data on social networks. 
In New Orleans, HIV-positive IDUs were located in areas predicted by low 
socioeconomic status and high density of alcohol outlets. After adjusting 
for other variables, however, the spatial structure was insignificant. The 
authors concluded that the possible “residual spatial structure” in adjusted 
analyses would have been attributable to core group members.230 In Canada, 
the IDUs most central to their network engaged in risky injection practices 
in the locations where the highest prevalence rates occurred. Using social 
network analyses, this study showed how specific hotels within the locality of 
Winnipeg played a key role in generating opportunities for the transmission 
of HIV.231 
Spatial data on IDUs and services
Spatial data and geographical information systems have also served to 
visualise and to study the distribution of IDUs and the distribution of services 
targeted at IDUs. A study among 597 IDUs from Baltimore showed that the 
type and frequency of drug use were associated with specific geographical 
areas, independent of neighbourhood characteristics.232 In New York (1994-
1996), 81% of street-recruited IDUs living near syringe exchange services 
typically used a syringe exchange, compared to 59% of those who lived 
more than a ten-minute walk away.233 Recently, more research has been 
warranted on geographical place as well as on socio-spatial and political 
processes related to place that may help to determine were IDU-related HIV 
risk environments occur.227
2.2.6. social, economic and political context 
On an individual level, poverty is an independent risk factor for HIV 
infections.234 In addition, several sociodemographic factors are known to 
be independent risk factors for HIV infection among IDUs: IDU groups 
with a low level of education, young IDUs, divorced or separated IDUs, and 
homeless IDUs are at greater risk for HIV infection.235, 236 
Social and economic factors also have an impact at the population and 
country level. Studies have noted that IDU epidemics in transitional countries 
have emerged in eras of social, political or economic changes, which create 
a “risk environment” for HIV characterised by increased drug availability, 
increased injecting drug use, and a lack of sufficient coverage of evidence-
based responses to HIV outbreaks.237-239 In addition, also political barriers 
against harm reduction interventions such as NEP and opiate substitution, 
and stigma associated with IDUs may indirectly influence the spread of 
HIV.239, 240
The poor coverage of harm reduction programmes is not limited only 
to developing or transitional countries such as the former Soviet Union. In 
the US, for instance, political barriers to NEPs are commonplace, even if 
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the number of programmes has increased throughout 1990s.181 In a cross-
sectional analysis of 96 US metropolitan areas, the prevalence of HIV among 
IDUs was significantly higher in those areas where laws prohibit over-the-
counter syringe sales. However, these laws were unassociated with lower 
population proportions of IDUs.241 In a later study, the same researchers 
reported that a number of police employees, corrections expenditures and 
drug arrests were positively associated with the prevalence of HIV among 
injectors. The conclusion was that legal measures had little deterrent effect 
on drug injecting, and may even contribute to an increase in the number 
of HIV infections.242 
Legislation has also prohibited NEPs in Sweden. A study that compared 
HIV incidence, prevention activities and legislation in Norway, Sweden 
and Denmark found that HIV incidence and prevalence in the early 1990s 
remained highest in Denmark, where NEPs were available, but where testing 
was reduced. In contrast, Sweden had strict legislation, but high testing rates; 
HIV incidence and prevalence there was lower. The researchers concluded 
in 2003 that HIV testing and counselling may be more effective than legal 
access to needles and syringes.243 In 2006, however, the number of HIV 
positive IDUs in Stockholm rose, which resulted in changes in legislation 
that permitted needle exchange programmes.
39
3. AIMS
The purpose of this study was to characterise the Finnish HIV outbreak 
among IDUs in order to recognise factors that have influenced the spread 
and restriction of the outbreak, and thus find tools for HIV prevention and 
control.
The specific aims of this present work were as follows:
To compare markers for disease progression (CD4 cell count and I. 
HIV viral load) between Finnish IDUs infected by the   
recombinant subtype CRF01_AEFin and Dutch IDUs infected by 
subtype B of HIV; 
To study the sociodemographic profile and spatial distribution of II. 
HIV-infected IDUs diagnosed in the beginning of the HIV  
outbreak and those diagnosed later;
To study the prevalence and determinants of unprotected sex III. 
among HIV-positive and HIV-negative Finnish IDUs, and thus to 
examine the potential of the sexual transmission of HIV within 
and from this population;
To study the characteristics of and trends in newly diagnosed IV. 
HIV cases in sub-epidemics among Finnish IDUs, MSM and  
heterosexuals, and to identify risk factors for late HIV diagnosis 




4.1. Comparison of CRF01_AEFin and subtype B of HIV (I)
Study population and data collection
The study population comprised 93 HIV-positive IDUs who were confirmed 
to be infected with CRF01-AEFin, had at least one available CD4 cell count or 
viral load measurement, and had visited the outpatient clinic of the Infectious 
Disease Clinic at Helsinki University Central Hospital at least once prior to 
November 2001. Only individuals with a seroconversion interval of under 
two years were included. The Finnish cohort was compared to 63 IDUs from 
the Amsterdam Cohort Study (ACS) who met the same inclusion criteria, 
but the IDUs were infected with subtype B (Table 5).
For each Finnish participant, patient documents were used to establish 
age, sex, and main illicit drug used, the date of previous negative HIV 
antibody tests and the date of the first HIV-positive test, CD4 cell counts 
and viral loads, and AIDS-defining illnesses. 
In the Amsterdam Cohort Study, participants were continuously recruited 
from 1985 onwards and were followed every four months. At every visit, 
they were interviewed for information on their health status, behaviour and 
illicit drug use; underwent a physical examination and had blood drawn for 
laboratory tests. IDUs included in the study were HIV-negative at entry and 
seroconverted during follow-up.244
Seroconversion was assumed to have occurred at the midpoint between 
the dates of the last negative and the first HIV-positive test. The date of the 
last HIV-negative test was documented for 58 (62%) Finnish individuals and 
for all 63 Dutch individuals. For the 35 (38%) Finnish IDUs without a date, 
it was estimated to be 1 July 1997 based on the following considerations. 
In March 1998, the first CRF01_AEFin case was reported to the National 
Registry of Communicable Diseases. By the end of 1998, a sudden increase 
in the number of HIV-positive IDUs had been observed in prisons and 
at the Infections Disease Clinic of the University Hospital, whereas no 
HIV-positive IDUs had been identified in 1997 despite 919 HIV antibody 
tests performed only in prisons (Leena Arpo and Matti Ristola, personal 
communication). Finally, there was very low genetic interpatient variation 
between the CRF01_AEFin sequences (< 0.5% in hypervariable regions).7 
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Table 5. Inclusion criteria of HIV-positive injecting drug users (IDUs) in the four 
sub-studies, study periods, and material combined or compared with the study 
population of Finnish HIV-positive IDUs. To be included in any of the sub-studies, the 
participants must have visited the Helsinki University Central Hospital at least once.
Study population of HIV-
positive IDUs
Compared  or combined 
with 
Study I
Comparison of  
CRF01_AEFin                      
and subtype B 
93 IDUs  
Infected with                       
CRF01_AEFin
(1998-2001)
63 Dutch IDUs 







•  Socioeconomic and 
geographical data  
available 
Geographical distribu-
tion of employed males 
in the Helsinki metropoli-
tan area by zip codes 
(City of Helsinki,              
Statistics Unit)
Study III
Unprotected sex among 
IDUs




207 HIV-negative IDUs 
 Riski study 
(2000-2002)
Study IV








At both sites, antibodies to HIV were determined by ELISA and confirmed 
by western blot. At every visit, T lymphocyte cell subsets were determined 
by using flow cytometry on fresh specimens. In Finland, the viral load 
was determined with the Amplicor HIV Monitor test version 1.5 (Roche 
Diagnostic Systems, Branchburg, NJ). The lower limit of primary quantitation 
was 400 copies/ml and later 400 or 50 copies/ml. In Amsterdam, the viral 
load was determined with NASBA, with a lower quantitation limit of 1000 
copies/ml (Organon Teknika, Durham, NC). The genetic subtyping of patient 
viruses was determined by sequencing and phylogenetic analysis of the 
Seroconversion interval < 2 years•	
At least one CD4 measurement or •	
viral load available
Risk behaviour  inverview available•	
CD4 cell count available within 90 days •	
of the first visit
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env V3 region, and in Finland, also the gag p7 regions from patient plasma 
samples, as described elsewhere.7, 245
Data analysis and statistics
Simple descriptive statistics were used to describe the basic characteristics of 
the study population. Differences between the cohorts were tested using the 
chi-square test, Student’s t-test or Mann-Whitney U test, as appropriate.
The random effects truncated probit model was used to compare the 
development of the HIV viral load over time after seroconversion. Values 
below the lower detection limit were treated as left censored; values above 
the upper detection limit were treated as right censored.246 In this model, 
all viral load measurements were included, except for those points at which 
antiretroviral therapy was used and for those measured after AIDS diagnosis. 
Viral loads were log-transformed in statistical analyses. Each individual 
was allowed to have his or her own intercept and slope around an average 
population intercept and slope. For viral load, the slope was allowed to differ 
during the first six months. A Bayesian approach was used to estimate the 
parameters, beginning with non-informative priors. Posterior distributions 
were obtained with the Markov Chain Monte Carlo methods, using the 
WinBUGS programme. Three chains were generated, based on different 
sets of starting values. Parameter estimates are the medians of the posterior 
distributions. The range from the 2.5% to the 97.5% quantiles served to 
quantify the uncertainty in the parameter estimates. This range can be 
interpreted as a 95% confidence interval (CI) and was referred to as such. If 
the value zero was outside this interval, the effect was considered statistically 
significant.  
To compare absolute CD4 cell counts and CD4 decline since HIV 
seroconversion, regression analysis for repeated measurements using a 
linear mixed model approach was used. Absolute CD4 cell counts were 
square root-transformed. The regression model, which was developed for 
the comparison of two cohorts, has been described in detail earlier.247
Statistical analyses were carried out using SPSS version 9.0 (Norusis; SPSS 
Inc., Chicago, IL, USA), SAS version 6.12 (SAS Institute Inc., Cary, NC, 
USA), and WinBUGS 1.3 (MRC Biostatistics Unit, Cambridge, UK). 
4.2. Sociogeographical profile of HIV-positive IDUs (II)
Study population and data collection
The study population consists of 176 HIV-infected IDUs, on whom 
sociodemographic and geographical background data were available. Of 
the 213 IDUs who had visited the Infectious Disease Clinic at HUCH at least 
once prior to October 2003, 83% were included in this sub-study.
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Since the first three cases of the HIV outbreak among IDUs in the Helsinki 
metropolitan area were detected, HIV-positive patients were interviewed 
regarding their history of injecting drug use, income, housing, education, 
work, history of addiction care, and imprisonment. Because many of the 
first cases were noticed to occur in clusters, IDUs were also asked in which 
areas they had been living or using drugs around the time of their first HIV-
positive test result or at the time of infection. Participants could list up to 
four different geographical areas. 
During the HIV-positive IDUs’ first visits to the Infectious Disease Clinic, 
data were initially collected by a social worker through semi-structured 
interviews for sociomedical purposes. After September 2002, these same 
data were obtained as part of a cohort study among HIV-positive IDUs. The 
CD4 cell counts were collected from the hospital data system. The CD4 cell 
measurements within 100 days of the IDUs’ first HIV-positive test results 
were included.
The socioeconomic data describing the spatial structures of the city in the 
Helsinki metropolitan area were obtained from the City of Helsinki Statistics 
Unit. The indicator used was the percentage of employed males aged 25 to 
64. This age limit aimed to exclude students and the elderly.248
Data analysis and statistics
To detect possible differences in the sociodemographic characteristics of 
the 176 participants, the early HIV-positive IDU cases newly diagnosed 
between 1 April 1998 and 31 March 2000 (n=98) were compared to recent 
cases (n=47) diagnosed between 1 April 2001 and 31 March 2003. To obtain 
maximum contrast, 31 cases between the groups were excluded. The analyses 
were also repeated without exclusion of the cases, and the data were divided 
in two by 30 September 2000.
To describe the geographical dynamics of the HIV outbreak in the 
Helsinki area, the areas where the IDUs reportedly lived or used drugs were 
converted into zip codes. The geographical distribution of the areas where 
the HIV-positive IDUs had been living or using drugs was projected onto 
maps showing the spatial differences in male employment. 
Simple descriptive statistics were used to describe the basic characteristics 
of the study population. Differences between early and recent cases were 
tested using the chi-square test, Student’s t-test or Mann-Whitney U test, 
as appropriate. Statistical analyses were carried out using SPSS version 10.0 
(Norusis; SPSS Inc., Chicago, IL, USA). The geographic distribution of the 
HIV cases was analysed using MapInfo Professional version 7.0 (MapInfo 
Corp., Troy, NY, USA).
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4.2. Unprotected sex among IDUs (III)
Study populations and data collection
This study combines data from two cohort studies on IDUs from the Helsinki 
metropolitan area (Table 4). The HIV-positive participants were recruited 
from among HIV-positive IDUs who were referred to the HUCH between 
1998 and 2004, and who had a seroconversion interval of less than two years. 
Of 225 IDUs, 89 (39.6%) were included in this prospective study, known as 
the Helsinki Cohort Study (HCS). The intake interviews were conducted 
over the years 2002, 2003 and 2004. 
The HIV-negative participants (n=207) came from the Riski study.249 
Participants were recruited from among needle exchange programme users 
in three Finnish cities over the years 2000, 2001 and 2002. In our study 
population, we included only subjects who were interviewed in the Helsinki 
metropolitan area, and who were found to be HIV-negative in an oral fluid 
test. The original study design has been described in detail elsewhere.249
In both cohorts, only participants 18 years of age and older were 
included. All the interviews were conducted according to a standardised 
questionnaire. Questions about sociodemographic background, detailed 
drug use, and risky injecting and sexual behaviour were the same in both 
cohorts. Questions regarding behaviour and use of services referred to 
the six months immediately prior to the interview. The participants were 
also interviewed regarding any sexually transmitted diseases diagnosed, 
their use of needle exchange services, and their use of addiction care 
services (inpatient, outpatient, and through which institution) as well as 
hospitalisations and periods of imprisonment. 
Data analysis and statistics
The combined anonymous data set includes baseline data on the two cohort 
studies and consists of 296 cases. The outcome was inconsistent condom 
use, defined as having unprotected sex with any sexual partners within the 
past six months (used condoms never, sometimes or most of the time). 
Consistent condom use was defined as always using condoms.
Simple descriptive statistics served to describe the basic characteristics 
of the study population. Risk factors for inconsistent condom use were 
analysed with logistic regression using forward and backward selection 
procedures. In multivariate analyses, risk factors for inconsistent condom 
use were analysed based only on those participants who reported having 
sexual partners within the past six months. The analysis was carried out 
with SPSS 14.0 (Norusis; SPSS Inc., Chicago, IL, USA).
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4.4. Epidemiology of late HIV diagnosis in Finland (IV)
Study population and data collection
The study population comprised 934 newly diagnosed HIV-positive patients 
in the HUCH area between the years 1985 and 2005. The included individuals 
were over 16 years of age, had visited the clinic at least once, and had a CD4 
cell count available between the HIV diagnosis and within 90 days of their 
first visit to the clinic. All patients were antiretroviral naive. By the end of 
2005, NIDR had received 1211 notifications of HIV cases from the HUCH 
area. Of 1083 patients who had visit the Aurora Hospital at least once, 86% 
were included. Individuals referred by other hospitals that provide care for 
HIV infection were excluded as were 16 cases whose first visit took place 
prior to the July 1985 introduction of the HIV test in Finland (Jukka Suni, 
personal communication). 
Sociodemographic data, possible earlier HIV-negative tests, date of first 
HIV-positive test, place of HIV diagnosis, date of referral and first visit to 
the clinic, AIDS-defining illness, death, and end of follow-up were recorded 
in the dataset. The data were collected from patient documents up to 1997. 
After 1997, data were available from the observational clinical database of the 
Infectious Disease Clinic and were complemented with patient documents. 
CD4 cell counts were available from patient documents, referrals, as well as 
from the hospital data system. Follow-up data (AIDS-defining illnesses and 
deaths) were included until the last visit prior to January 2006 or death.
Data analyses and statistics
Late diagnosis was defined as having a first CD4 count below 200 cells/µL or 
having AIDS (according to the 1993 European AIDS case definition) within 
90 days of the HIV diagnosis.65 Delayed entry to care was defined as having 
first visited the clinic more than six months after the HIV diagnosis. Newly 
diagnosed was defined as those referred directly to the Infectious Disease 
Clinic at HUCH after their first HIV-positive test. 
Health care-related diagnosis was defined as having had the first HIV-
positive test performed in primary health care (health centres, private 
doctors or occupational health care) or in secondary health care (hospital 
wards or outpatient clinics). Non-health care-related diagnosis included 
HIV diagnoses made at prisons, NEPs, immigrant centres, drug treatment 
or non-governmental AIDS support centres. Sub-epidemics were defined 
according to transmission mode (heterosexual, MSM, IDU).
Study period was divided into five four-year intervals based on the year 
of HIV diagnosis (1August 1985-1989, 1990-1993, 1994-1997, 1998-2001, 
2002-2005). The four-year interval was selected in priori based on the fact 
that the epidemic among IDUs began in 1998. The analysis was repeated 
using the year 1997 as an alternative cut-off in order to analyse the possible 
47
effect of cART. The interval 1985-1989 was defined as the first stage of the 
sub-epidemic among MSM and heterosexual cases. The other periods were 
defined as subsequent stages of the epidemic.  
SPSS 15.0 (SPSS Inc, Chicago, IL, USA) was used for statistical analysis. 
Chi-square tests, t-tests and Mann-Whitney tests served to test for differences 
between the groups. The multivariable logistic regression model served 
to identify factors independently associated with late HIV diagnosis and 
delayed entry to care. For data validation, the analysis was repeated using 
a 90-day cut-off for time between the HIV diagnosis and the first CD4 
count.
4.5. Ethical aspects
The Helsinki Cohort Study among HIV-positive IDUs was approved by the 
Ethics Committee, Department of Medicine. The Riski study was approved by 
the Ethics Committee of Epidemiology and Public Health, Hospital District 
of Helsinki and Uusimaa. The Ethics Committee of Epidemiology and Public 
Health approved the combination of the cohorts. The participants have 





5.1. Comparison of CRF01_AEFin and subtype B (I)
General characteristics
No significant differences occurred between the 93 Finnish and the 63 Dutch 
IDUs in mean age at HIV seroconversion (32 vs. 32 years), gender (72% 
vs. 59% male) or years since beginning injecting drug use (9 vs. 10 years). 
The main narcotic substance used was amphetamine for 51% of Finnish 
IDUs, whereas in Amsterdam, 57% injected speedballs (heroin together 
with cocaine). 
The median seroconversion interval was longer in Finland than in ACS 
(12.8 months vs. 3.9 months, p<0.05). The seroconversions occurred between 
1997 and 2001 among the Finnish IDUs, and between 1986 and 1996 among 
the Dutch IDUs. In the Finnish study cohort, the maximum number of HIV 
seroconversions occurred in 1998 (Figure 2). 
The follow-up was restricted to 48 months in the ACS, but the median HIV-
positive follow-up was still slightly shorter in Finland (24.3 vs. 29.8 months). 
During the follow-up, four Finnish IDUs died, and one was diagnosed with 























The Finnish study cohort
NIDR
Figure 2. The estimated year of HIV seroconversion for the Finnish study cohort, and 
the year of first positive HIV test result for all injecting drug uses (IDUs) as reported 




CD4 cell decline and HIV viral loads
The median number of CD4 measurements per individual was four (range 
0-15) in Finland and six in the ACS (range 1-13). For both sites, the median 
number of viral load measurements was four (0-14).
No statistical difference occurred in CD4 cell level or in CD4 cell decline 
between the Finnish and the ACS cohort during the 48-month follow-up 
period. The predicted CD4 decline after six months since seroconversion 
was 67 cells/µL per year in the Finnish cohort and 64 cells/µL per year in the 
ACS. The predicted CD4 lymphocyte levels six months after seroconversion 
were 535 and 551 cells/µL, and after 24 months, 425 and 446 cells/µL, 
respectively.
In the random effect truncated probit model, Finnish IDUs exhibited 
higher viral loads throughout the follow-up period (Figure 3). When 
analysis was repeated only for those 24 Finnish seroconverters with a 
narrow seroconversion interval (<6 months), the difference in the viral load 
between the Finnish and Amsterdam narrow seroconverters was statistically 
significant from 12 to 48 months after seroconversion. 
When the analysis of viral loads was repeated including all the 
measurements after the administration of ART or after AIDS diagnosis, 
the proportion of participants with one or more excluded measurements was 
the same in both cohorts (10%). In this analysis, the model shows still higher 
viral loads in the Finnish cohort, and the difference between the cohorts 
was significant from 6 to 24 months after seroconversion. After correcting 
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Figure 3. A) HIV RNA loads (log copies/ml) in Finland and Amsterdam. B) HIV 
RNA load difference (log copies/ml) between the Finnish and the Amsterdam cohort. 
Random effect model allowing for left and right censored data, 95% confidence 
intervals.
5.2. Sociogeographical profile of HIV-positive IDUs (II)
General characteristics
Of all the 176 HIV-positive IDUs, the mean age was 33 (16-63 years), 86.4% 
were living in Helsinki city, and 72.2% were male. Only 1.9% were employed 
at the time of the first interview, 22.4% had been working within the past 
five years, and for 43%, the main source of income was social security. The 
number of homeless (no official address) was 65.3%, and 82.0% had fewer 
than nine years of education, 15.1% were living with a partner, and 35.3 
% had children (<18 years), but only 10.5% of them were living with their 
children; 43.5% had been admitted to a psychiatric hospital care at least 
once.
The sociodemographic characteristics of the 98 early and the 47 recent 
cases appear in Table 6. The recent cases were significantly older, and had 
used injecting drugs for a longer period than had the early cases. There 
were no significant differences between the early and recent cases in the 
proportion of young drug users (age <25 years, 14.3% vs. 6.4%) or in the 
proportion of IDUs who had begun injecting for fewer than five years prior 
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Additional analyses that either exclude cases interviewed more than one 
year after HIV diagnosis or include cases between April 2000 and March 
2001 yielded similar results.
Table 6.  Sociodemographic characteristics of early and recent HIV-positive injecting 
drug user cases in the outbreak in the Helsinki metropolitan area (early cases: first 
HIV-positive test between 1 April 1998 and 31 March 2000; recent cases: first HIV-






Age (years, mean, range)* 32 (16-56) 36 (20-62) <0.05  
Male (%) 70.4% 78.3% 0.323
Main drug amphetamine 74.1% 77.8% 0.670
Duration of injecting 
(years, mean, range)*
10.7 (0-32) 14.3 (1-37) <0.05  
Homeless 66.3% 66.0% 0.966
In employment 2.2% 2.4% 0.801
History of imprisonment 74.7% 72.3% 0.762
Lack of further education (<9 years) 83.8% 84.4% 0.919
History of addiction rehabilitation or 
detoxification or both
61.7% 70.5% 0.109
First CD4 count (cells/µL) 579 431 <0.01  
* at the time of the first HIV-positive test
Sociogeographical distribution of HIV-positive IDUs
The reported geographical areas where the IDUs lived or used drugs during 
the time of their HIV diagnosis appear in Figure 4. Among recent cases, 
only one additional area (suburb of Myyrmäki) was mentioned. When the 
distribution of employed males was compared to the distribution of areas 
mentioned by the IDUs, a consistent pattern emerges: all IDU clusters outside 
the city centre are located in areas with low male employment rates.
When examining the two largest geographical clusters outside the 
downtown separately, 39% (15/38) of the persons who lived or used drugs 
in the suburb of Maunula, and 40% (8/20) of those in the suburb of Malmi, 
did not mention the centre of Helsinki as one of the areas.
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Figure 4. Geographic areas in the Helsinki metropolitan area, where the HIV-positive 
injecting drug users (IDUs) lived or used drugs during the time of the HIV diagnosis, 
and male employment rate. Map A shows the areas reported by the early cases, map B 




5.3. Unprotected sex among IDUs (III)
General characteristics
Several significant (p<0.05) differences emerged in the characteristics of the 
HIV-positive and HIV-negative IDUs. The HIV-positive IDUs were older 
(median age 36 vs. 26 years), more often unemployed (98% vs. 89%), and 
hepatitis C antibody-positive (96% vs. 51%) than were the HIV-negative 
IDUs. The main drug was amphetamine for 52% of the HIV-positive 
participants and for 36% of the HIV-negative participants. Of the HIV-
positives, 78% had a history of imprisonment and 72% reported injecting 
in the past six months, whereas the proportions among the HIV-negatives 
were 38% and 100%, respectively. 
Of the HIV-positive IDUs, 28% had undergone inpatient addiction 
treatment (with or without outpatient treatment), 56% had undergone 
outpatient treatment only, and 26% had used no addiction treatment services, 
whereas the proportions among the HIV-negative group were 57%, 10% and 
33%, respectively. At the time of the interview, 18% of the HIV-positive 
IDUs were on methadone substitution treatment and 2% on buprenorphine 
substitution treatment, whereas the proportion in the HIV-negative group 
was 0.5% and 7%, respectively.
Of the HIV-positive IDUs, 18% reported having lent needles, syringes or 
other injecting equipment at least once in the past six months. Borrowing 
or lending injection equipment was reported by 62% of the HIV-negative 
IDUs.
Sexual behaviour 
The sexual behaviour of the HIV-negative and HIV-positive IDUs appears 
in Table 7.The HIV-negative participants were more often sexually active 
than were the HIV-positives (87% vs. 70%). Inconsistent condom use was 
reported by 63% (39 of 62) of the HIV-positive and 80% (144 of 181) of the 
HIV-negative sexually active IDUs. Of the HIV-positive IDUs, 33% had 
multiple sex partners compared to 42% of the HIV-negative group. Among 
the male IDUs, 2% of the HIV-positive participants and 4% of the HIV-
negative participants reported having sex with other males.
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Table 7. Sexual behaviour of HIV-positive and HIV-negative injecting drug users in 






Number of partners 
   0
   1
   2-6










   Steady partner only
   Casual partner only
   Steady and casual









Inconsistent condom use with*
   Steady partner
   Casual partner
   Commercial sex partner









No condom/last occasion with*
   Steady partner
   Casual partner








diagnosed 8 (9.0%) 4 (1.9%)
* Percentages of those who have a partner
Factors associated with inconsistent condom use
In univariate analysis, inconsistent condom use was more common among 
HIV-negative IDUs than among HIV-positive IDUs, and was more common 
in steady relationships in both groups. In addition, inconsistent condom use 
was more common among those IDUs who had received inpatient addiction 
treatment within the past six months than among those who had received no 
such treatment (p<0.10). In multivariate analysis, the association between 
addiction treatment and inconsistent condom use differed according to HIV 
status. For the HIV-positives, inconsistent condom use was associated with 
in- and outpatient treatment, whereas for the HIV-negatives, inconsistent 
condom use was associated only with inpatient treatment (Table 8).
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In this study, inconsistent condom use showed no independent association 
with age, gender, marital status, number of sex partners, commercial sex, 
STIs, drug use frequency, NEP use, or duration of injecting. Furthermore, 
inconsistent condom use showed no association with education, unstable 
living, unemployment, recent imprisonment (within the past 6 or 12 months) 
or number of imprisonments. Among those who reported no drug use, but 
had sexual partners, 56% (9/16) reported inconsistent condom use.
When the logistical regression analysis was repeated to include those 
IDUs who reported having no sexual partners in the past six months, the 
results were similar. Likewise, the results remained the same after excluding 
the 16 HIV-positive IDUs who had known HIV-positive partners, and 
after excluding the 22 participants who reported no drug use in the past 
six months. 
Table 8. Factors related to inconsistent condom use in the past six months. Because 
of interaction between substance abuse treatment and HIV status, odds ratios (OR) 
appear separately according to HIV status. Injecting drug users (IDUs) who reported 
having had no sex (n=54) were excluded. 
Variable Inconsistent condom 
use 
OR (95% CI) in the 
multivariate model
Partner type
   Steady partner only
   Casual partner only








   Substance abuse treatment
   Inpatient
   Outpatient only











   Substance abuse treatment
   Inpatient
   Outpatient only








* OR 4.2 (1.2-15.2) compared to the outpatient group
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5.4. Epidemiology of late HIV diagnosis in Finland (IV)
General characteristics of newly diagnosed HIV cases 
Of all 934 cases, 26% were IDUs, 31% heterosexuals, and 42% MSM. 
The transmission group for 11 cases was either other or unknown. The 
characteristics of the study population divided into four-year calendar 
periods of HIV diagnosis appear in Table 9. The study population represents 
77% of IDU, 66% of MSM and 42% of heterosexually transmitted HIV cases 
reported to the National Infectious Disease Registry nationwide between 
1985 and 2005 (n=1597). 
Table 9.  Characteristics of newly diagnosed HIV patients and proportion of late 
diagnosed HIV cases in the study.















31 (25-37) 31 (26-38) 33 (28-40) 34 (28-40) 36 (30-42) 33 (28-40)
Male 90% 76% 68% 73% 81% 77%
Finnish 
nationality
89% 83% 72% 90% 82% 84%
Previously 
tested
20% 44% 45% 48% 56% 45%
HIV-negative 
test within 2 
years 
17% 31% 22% 32% 29% 28%
Late-diagnosed 
cases
     IDU 2/8            
(25%)
1/3             
(33%)































Late diagnosis among newly diagnosed HIV cases
Of all cases, 195 (21%) presented with a CD4 count of fewer than 200 cells/
µL, 59 (6%) with a CD4 of <50 cells/µL, and 80 (9%) presented with AIDS. 
Altogether, 211 (23%) were classified as late diagnoses (CD4 <200 cells/
µL, or AIDS within three months of HIV diagnosis). Within the first year 
after HIV diagnosis, 98 (11%) were diagnosed with AIDS. The median CD4 
count was 419. 
The proportions of late-diagnosed individuals and predictors of late diagnosis 
in the multivariate model appear in Table 10. Individuals diagnosed late were 
more often older (>40 years), male, non-IDUs, non-Finnish, and less likely 
to be tested before. Late-diagnosed individuals were more often diagnosed in 
primary health care or in secondary health care than in STD clinics.
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Late diagnosis was rare before 1990 and between 1998 and 2001. These 
four-year periods overlapped with the early stages of identifiable sub-
epidemics: the MSM and heterosexual sub-epidemic prior to 1990, and 
the IDU outbreak in 1998-2001 (Figure 5). When multivariate analysis 
was repeated using the variable “stage of the epidemic” instead of calendar 
periods, the later stage of the outbreak was found to be a strong independent 
predictor (OR 4.3, 95% CI 2.5-7.4) for late diagnosis. The cART era failed 
to change the proportion of late-diagnosed cases among heterosexual and 
MSM transmissions. The IDUs were excluded from this analysis, since the 
outbreak occurred after introduction of cART.
Table 10. Prevalence and predictors of late HIV diagnosis.






   Finnish






Age at HIV diagnosis
   <30
   30-39








Transmission group and gender
   IDU female
   IDU male
   Hetero female
   Hetero male













   1985-1989
   1990-1993
   1994-1997
   1998-2001













Stage of the epidemic *
   First






Previously tested HIV- negative
   Yes






Site of HIV diagnosis        
   STD clinic
   Primary health care
   Secondary health care
   Non-health care





































































































































































































































































Figure 5. Median CD4 cell count, annual number of newly diagnosed HIV cases, and 
number of late-diagnosed HIV cases in sub-epidemics among men who have sex with 
men (MSM), heterosexuals, and injecting drug users (IDUs) in the HUCH area, and 
annual number of HIV cases reported to National Infectious Diseases Register from 
Finland.
Site of HIV diagnosis
Of the heterosexually transmitted cases, 71% were diagnosed as HIV-positive 
in primary or secondary health care settings, whereas the proportion among 
MSM and IDU groups was 56% and 40%, respectively. Prisons, needle 
exchange sites or drug treatment facilities diagnosed 49% of the HIV cases 
among IDUs (Table 11). 
 Despite the stable proportions over calendar periods in all diagnoses 
made in health care settings, primary health care diagnosis decreased from 
35% to 13% among late-diagnosed cases.
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Table 11. Sociodemographic characteristics, testing behaviour and delays in HIV cases 








Age, median, years  (IQR)* 35 (28-41) 31 (27-40) 34 (28-40)
Male 76% 46% (100%)
Finnish nationality 96% 62% 93%
Testing status
   Previous HIV-negative test 
   available (%)
50% 38% 48%
   HIV-negative test within 2 years 36% 21% 28%
Site of HIV diagnosis
   Primary health care   
   Secondary health care
   STD clinics
   AIDS support centre 
   Prisons
   NEPs
   Drug treatment
   Immigrant centre
   Other
































   HIV-positivity to referral 15 14 14
   Refererral – First visit 32 16 17
   HIV-diagnosis – first CD4 44 33 34
   HIV-diagnosis – first visit 59 34 35
*Interquartile range
Delayed entry to HIV care
The median delay from the HIV diagnosis to the first visit at the Infectious 
Disease Clinic was 1.3 months. The delay was shortest for female heterosexuals 
(median 1.1 months) and longest for male IDUs (median 2 months). Of all 
cases, 11% were delayed for more than six months, and 4% for more than 
two years. Of the IDUs, 20% were delayed for more than six months.
In the multivariate model both, female IDUs (OR 5.0, 95% CI 2.0-12.1) 
and male IDUs (OR 3.9, 95% CI 1.9-7-9) were more likely than MSM to enter 
HIV care late. Delayed entry to care was more common prior to 1998, and 
was also associated with non-Finnish ethnicity (OR 2.3, 95% CI 1.3-4.11). 
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6. DISCUSSION
Finland’s geographical location between the East and West is reflected in the 
spread of HIV. Whereas Western-type sexual epidemics spread in the 1980s, 
the Finnish outbreak among IDUs spread late, but explosively, similar to 
the concurrent outbreaks in the former Soviet Union. However, this study 
describes characteristics of one of the few IDU epidemics to revert very 
quickly, and where the prevalence of HIV among IDUs remained low. 
Finland’s relatively isolated northern geographic location may also have 
contributed to the late introduction of HIV in Finland, which allowed 
the early detection of the epidemics that appear in this study. This early 
detection, followed by early response, may have contributed to the low HIV 
prevalence in the country. 
Perhaps most importantly, this study shows the geographical spread and 
restriction of the HIV epidemic among IDUs on a smaller scale, at the city 
and neighbourhood level. The results show that in low prevalence countries, 
high-risk groups may be concentrated in deprived areas, or “pockets of 
poverty”, and poses a strong argument in support of outreach work, the 
decentralisation of services, and rapid responses.
Even if this study covers only some of the factors that may have influenced 
the spread of HIV, it allows discussion of the spread and restriction as well 
as the risk for further spread of the HIV outbreak among Finnish IDUs 
in light of the results, surveillance data, and published studies available 
from other countries. Study IV also creates an opportunity to compare 
this IDU outbreak with other Finnish sub-epidemics among MSM and 
heterosexuals.
6.1. Rapid spread of the outbreak (I,II)
The spread of HIV among Finnish IDU was even more rapid than official 
statistics suggest. This study shows that the majority of seroconversions 
occurred as early as in 1998, whereas the peak in incidence in the Finnish 
reporting system occurred in 1999. Since the median CD4 counts were high 
in the early years of the outbreak, the sharp rise in new HIV cases cannot 
be due only to increased testing, but rather reflects a recent increase in new 
transmissions.  
The HIV viral load is associated with infectivity.210-214 The viral load is 
high in the early stage of the infection, which renders recently infected 
IDUs particularly infectious and enables the rapid spread of HIV. In this 
62
study, the viral load was higher in the Finnish cohort infected with subtype 
CRF01_AEFin than in the Dutch IDU cohort infected with subtype B, which 
may have facilitated the explosive spread of CRF01_AEFin among Finnish 
IDUs. 
The results indicate that the period of higher probability of transmission 
may be longer in CRF01_AEFin-infected persons, at least compared to 
individuals infected by subtype B. Viral loads declined in both subtypes, 
but the decline was slower in the Finnish cohort, and the difference between 
the subtypes increased during the two-year follow-up. 
According to results from Uganda, the risk for transmission is 26 times 
higher during the primary infection than later in the course of HIV infection, 
but only for a three-month period.215 Among heterosexuals, the impact of 
this early period was considered short in relation to the long asymptomatic 
phase of the infection. However, the early period carries greater weight 
among IDUs, since the number of high-risk situations and sharing partners 
may be large, and the probability of transmission associated with unsafe 
injecting is higher than with sexual contacts.3
Since the difference in viral load between the subtypes was relatively 
modest, we must take into account the possible impact of different quantitation 
assays. Previous versions of the assays are known to underestimate viral loads 
in non-B subtypes. In the present study, both cohorts were analysed with 
an assay that is sensitive to the prevalent subtype: NASBA for subtype B 
and Amplicor for subtype CRF01_AEFin. Our own analysis and calculations 
based on previous studies indicate that had Amplicor 1.5 been used for both 
cohorts, the viral loads for subtype B would have appeared slightly lower, 
and thus the differences between the cohorts even greater.250-252 
A recently published study suggests that relatively small changes in viral 
loads may affect the transmissibility of HIV.216 The researchers estimated that 
the likelihood of transmitting HIV through heterosexual contact increases 
by 20% with every 0.3 log10 increment in HIV RNA. The mean viral load 
difference between the Finnish and the Dutch cohorts varied between 0.34 
and 0.94 log10, and the lower 95% confidence interval exceeded 0.2 log10 
after the first year of follow-up. Thus, the observed higher viral load in the 
Finnish cohort may have contributed to the rapid spread of the outbreak.
The results of the present study are in accordance with the results of a 
cohort study in Thailand, where higher viral loads were found during the 
early period of HIV infection among persons infected with CRF01_AE than 
among those infected with subtype B; both were analysed with Amplicor 
1.5.52 In Thailand, subtype AE has also spread more rapidly than subtype 
B has, even if both were introduced to the IDU population.253 Similar 
differences in viral loads in the early stages of HIV infection have been 
observed in other comparisons between seroconverter cohorts (i.e. studies 
that allow comparison of the cohorts in relation to the time since estimated 
transmission).50, 53, 54 However, studies lacking seroconversion data seem 
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unable to detect such differences between subtypes, since these appear only 
in the early stages of HIV infection.40-45 
In addition to high viral load and infectiousness in early infection, other 
factors have also been associated with the rapid spread of HIV among IDUs. 
The lack of information about HIV and restricted access to clean needles 
and syringes combined with a high number of susceptible individuals in 
the naive IDU population have fueled HIV epidemics in many countries.254, 
255 Rapid spread may also be associated with situations that create fast risk-
partner changes (e.g. “shooting-galleries” where IDUs may share needles 
and syringes with many IDUs in a short period of time).255 
In the Helsinki metropolitan area, the number of IDUs was estimated 
to be as high as 7400 in 1998, and high incidence of hepatitis C (HCV) 
infections reflects the existence of risky injecting behaviour among this 
large susceptible IDU population. Qualitative information obtained during 
the structured interviews of this study also indicate a lack of information 
about HIV and other blood-borne diseases. Probably most importantly, 
this study describes the limited access to clean equipment in the beginning 
of the outbreak. 
NEP was implemented with limited resources in the city centre in 1997, 
and the other NEP centres were opened after 1999. In this study, two clear 
clusters of IDUs emerged outside the city centre. Up to 40% of the HIV-
positive IDUs who lived or used drugs in these clusters had no contact with 
the city centre of Helsinki. Thus, NEP failed to reach these geographical 
pockets of infection.
In addition to the insufficient geographical coverage of NEPs, the numbers 
of exchanged needles and syringes was only 74 000 in 1998, compared to 
1 108 000 in 2003.256 Since neither the amount of equipment distributed 
by pharmacies nor the number of IDUs in the area increased during that 
period, the coverage of the equipment was far from adequate during the 
first years of the outbreak, when the majority of transmissions occurred as 
early as in 1998. 
The number of exchanged equipment can also serve as a surrogate for 
other prevention activities since these were included in Finnish NEPs, known 
as the Low Threshold Health Service Centers, from the beginning.256 Those 
IDUs unreached by clean needles and syringes were also less exposed to 
information, education, low-threshold testing, counselling and referrals to 
drug treatment. 
Conversely, access to clean equipment and other services improved 
rapidly, and is most likely one of factors that contributed to the limitation 
of the outbreak. 
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6.2. Rapid restriction of the outbreak (II)
In many countries, HIV incidence among IDUs peaks when the prevalence 
of HIV is high, and thus the number of susceptible IDUs in the population 
decreases. In the Helsinki area, this saturation effect fails to explain the 
limitation of the outbreak, since the number of IDUs was estimated to be 
as high as 7400 in the area, and fewer than 300 of them became infected 
with HIV.257, 258 
However, the results of the present study indicate that the outbreak was 
saturated in a core group of marginalised IDUs. Firstly, those IDUs infected 
with HIV in the later stage of the outbreak (2002-2003) were significantly 
older, had lower CD4 levels, and had used injecting drugs for a longer 
time than had those IDUs diagnosed in the beginning of the outbreak. 
Thus, they may at least partly represent the same core group as the early 
cases, only diagnosed later. Secondly, the HIV-infected IDUs were older and 
more marginalised than were the HIV-negative IDUs interviewed in the 
Riski study, which was conducted at needle exchange stations.249 Even if the 
selected material of the Riski study does not represent all IDUs, those results 
support the view that the sociodemographic profile of HIV-infected IDUs 
differed from that of the average IDU population in the area. Thirdly, this 
present study also shows the spatial clustering of HIV-positive IDUs. In the 
lack of specific network data, these clusters of IDUs found outside the city 
centre can be considered indirect signs of networking between the IDUs: the 
40% of individuals in clusters who had no contact with the city centre may 
also have had limited contact with other IDUs outside the clusters. 
Compared to the situation in Russia, the sociodemographical profile and 
spatial distribution of the HIV-infected Finnish IDUs contrast sharply.229 
In Helsinki, the HIV-infected IDUs were older, more marginalised, 
frequently homeless, and often had a history of imprisonment, addiction 
care, psychiatric care, and a long history of injecting drug use. The cases 
diagnosed in later stages of the outbreak were just as marginalised and came 
from the same neighbourhoods as did the early cases, and no new clusters 
were detected during the five-year study period. Only 10% of the cases were 
young (<25 years), and the proportion of young IDUs decreased during the 
study period.
In St. Petersburg, the HIV-infected IDUs were not only spatially clustered, 
but also co-clustered with a high frequency of heroin injection and receptive 
syringe sharing, and – most notably – being younger than 24 years of age 
and living with their parents. 229 Similarly, in Estonia, most HIV-infected 
IDUs belonged to the 15- to 24-year age group.23 Young IDUs may be more 
likely to transmit HIV further, because they are often more sexually active 
and may have little knowledge of HIV and safe injecting.235, 259 
Some studies suggested in the 1990s that HIV may enter the IDU 
population through marginalised groups of IDUs.260, 261 This study shows 
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that the Finnish epidemic spread in only a limited fashion outside this 
marginalised core group. However, HIV-negative IDUs were engaging in 
high-risk behaviour, as reflected in the high incidence of HCV and in the 
interviews of the Riski study among HIV-negative IDUs conducted shortly 
after the outbreak.126, 249 Without interventions, HIV would most likely have 
spread among the larger IDU population and caused a “second wave” of the 
outbreak within the area.
Nevertheless, several interventions were implemented, which may have 
contributed to the containment of the HIV epidemic. The first NEP began in 
1997 and offered clean needles, syringes, condoms, and health counselling 
and testing for HIV and hepatitis. In addition, pharmacies were encouraged 
to continue selling needles and syringes to IDUs. In response to the first HIV 
cases detected among IDUs, public information about a possible outbreak 
was disseminated through the media, and specifically at the NEP stations. 
The frequency of HIV testing increased, especially in prisons and at NEPs. 
Notably, almost one in three HIV infected IDUs was diagnosed at prisons 
during the first two years of the outbreak.
A study by Des Jarlais et al. described prevention activities and risk 
behaviour in cities where HIV was introduced to the IDU population, but 
the prevalence remained low (<5%).185 The three most common components 
of prevention were present in all five cities: the implementation of prevention 
activities when HIV prevalence was still low, easy access to sterile injection 
equipment, and community outreach to IDUs. As described above, the two 
first components were also present in the Helsinki metropolitan area. 
Some of the interventions began after the outbreak peaked, and have 
thus played no role in reversing the trend in HIV incidence. They may 
have influenced continued positive development, however. Since December 
2000, the day centre for HIV-positive IDUs offers a free low-threshold 
methadone programme, clean injection equipment, food, addiction care 
services, infectious disease specialist services, medication and social 
services. The centre has also improved adherence to antiretroviral therapy, 
which can reduce the risk of transmission by decreasing the viral load.219-221 
Furthermore, separate daily services have encouraged networking among 
HIV-positive IDUs, and may also have reduced their contact with HIV-
negative IDUs. One of the indirect indicators of this is the low proportion 
of HIV-positive clients in anonymous seroprevalence studies conducted in 
other NEPs despite the fact that a majority of HIV infected IDUs remain 
active drug users. 
Outreach programmes began in 2001, and have educated peer workers 
who distribute information, clean equipment and condoms for hard-to-reach 
IDUs outside the city centre. Peer work as well as HIV and health education 
programmes targeted at IDUs have been implemented in prisons as well.
Early detection of the outbreak and early diagnosis of HIV may also have 
led to similar positive changes in risk behaviour as reported in other studies 
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among IDUs.195, 196 In this study, HIV-positive IDUs reported significantly 
less risky injecting and unprotected sex than did HIV-negative IDUs. 
Unfortunately, this study has no pre-outbreak behavioural data.  
The Finnish HIV outbreak among IDUs occurred in a fairly stable 
socioeconomic and political situation compared to those in Estonia, Russia, 
and in many other transitional or developed countries. Although barriers to 
the acceptance of harm reduction programmes were common, the outbreak 
of HIV facilitated the diffusion of NEPs in the Helsinki metropolitan area, as 
well as in other parts of the country.262 Compared to many Western countries 
where the HIV incidence among IDU peaked as early as in the 1980s, much 
more evidence-based data on HIV prevention was now available, which 
could be put into action without significant delay.263 
6.3. Risk for further spread of HIV among Finnish IDUs (III)
Examples where HIV has spread again after years of stable HIV prevalence 
do exist.24 On the other hand, also in cities that succeeded in reverting HIV 
outbreaks, residual risk behavior has been reported. This study included no 
detailed analysis of injecting behaviour and determinants of risky injecting 
among HIV-positive and HIV-negative IDUs. It does, however, show that 
among the 296 IDUs included in the sexual risk behaviour analyses, up to 
18% of HIV-positive IDUs reported at least one lending episode, and 62% 
of HIV-negative IDUs reported having borrowed or lent equipment at least 
once in the past six months. 
The residual injection risk behaviour among HIV-positives is in line 
with that of other studies.147 The observed prevalence of risky injecting, 
combined with the HCV incidence of more than 350 cases from the HUCH 
area and the rising HCV incidence in northern Finland, indicates that a 
risk for HIV spread exists through unsafe injecting. Sharing is unlikely to 
become less common among those IDUs excluded from the Riski study, 
which was conducted within NEPs. Thus, the continuation, distribution 
and development of NEPs and of other prevention activities are of great 
importance. 
Several studies have shown the growing impact of sexual transmission 
on HIV epidemics among IDUs, especially in settings where prevention 
activities have successfully decreased injection-related risks.152, 153 This study 
shows that unprotected sex was common among Finnish IDUs. Up to 70% 
of IDUs reported inconsistent condom use, which is in line with the results 
of earlier studies. 
Compared to the study populations of many other studies, this study 
population was more marginalised.152, 157-160 On the other hand, this study 
also shows the high prevalence of risky behaviour despite the wide range 
of services available: HIV-positive IDUs were followed up in the Infectious 
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Disease Clinic, and HIV-negative people were active NEP users. In addition, 
the majority of IDUs in both groups had used addiction care services. 
However, structured HIV prevention targeted at sexual behaviour is offered 
to HIV-positives only during the first clinic visits. Of HIV-negatives, a 
minority reported that they had received counselling at NEPs about sexual 
behaviour.249 There exists a clear need to combine structured and repeated 
interventions targeted at sexual behaviour with these services offered for 
IDUs.
Having a steady partner is a known risk factor for unprotected sex among 
IDUs.264 In contrast, the association between recent addiction care and 
inconsistent condom use found in this study is an unexpected result. It 
must be noted that this sub-study was not designed to evaluate the effect of 
addiction care. Where most previous studies have been conducted during 
drug treatment and have had no positive effect on high-risk sexual behaviour, 
our study population consisted of active injectors. Despite this possible 
selection bias and small sample size, the results suggest the need for further 
studies, since similar results were obtained recently in a larger study among 
SIF users in Canada.161 
A more qualitative approach may help us to understand whether this 
higher-risk behaviour possibly reflects the chaotic life situation of IDUs 
prior to entering treatment, increased networking among IDUs in drug 
treatment, or increased sexual activity after such treatment. Nevertheless, the 
high prevalence of unprotected sex poses a risk for HIV to spread sexually 
among IDUs, and poses a huge challenge for health and addiction care 
workers who work with this difficult patient population. 
6.4. Characteristics of the IDU outbreak compared to 
sexual epidemics in Finland (I, IV)
When the characteristics of the IDU outbreak are compared to the Finnish 
epidemics among MSM and heterosexuals, some clear differences stand out. 
As discussed previously, the IDU outbreak spread later, spread faster, and was 
contained faster than were the epidemics among MSM and heterosexuals. 
Comparable to a study from Italy, Finnish IDUs were diagnosed earlier in 
their infection, but their delays in receiving HIV care were longer than for 
the MSM and heterosexually transmitted cases.91 The IDUs were also more 
likely to test HIV-negative earlier. Of particular importance, the IDUs were 
more often diagnosed at sites, such as NEPs, drug treatment or prisons, that 
may actively offer HIV testing combined with other services while up to 70% 
of heterosexuals and 60% of MSM were diagnosed in health care settings. 
Being diagnosed in non-health care settings as well as in STD clinics was 
also independently associated with earlier diagnosis, at least more so than 
in primary or secondary health care.
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However, some interesting similarities also exist between the IDU 
epidemic and the sexual sub-epidemics in Finland. The data show that 
the spread of HIV was detected early not only among IDUs, but also in 
sexual epidemics in the 1980s. In the IDU outbreak, only 6% of patients 
were diagnosed with low CD4 levels during the first four-year period. The 
median CD4 count of all IDUs diagnosed between 1998 and 2001 was 490 
cells/µL whereas the predicted CD4 count of seroconverters in study I was 
468 cells/µL 12 months after seroconversion. The recent spread of HIV was 
confirmed by the introduction of a novel, genetically homogenous HIV 
clone in the IDU population and in only a few HIV cases diagnosed among 
IDUs in previous years.7 
Notably, the proportion of late-diagnosed cases was low also in the first 
stage of the sub-epidemics among MSM and heterosexuals, and the median 
CD4 count was even higher than in the beginning of the IDU outbreak (545 
and 575 cells/µL, respectively). This early detection of each sub-epidemic 
allowed early responses, and provides one possible explanation for the low 
prevalence of HIV in Finland.
The other common feature in all epidemics was the increasing proportion 
of late-diagnosed cases in later stages of the epidemics. Late diagnosis was 
rare in the first four-year period of each sub-epidemic, but became more 
common thereafter. Regardless of transmission group, the subsequent, later 
stage of the epidemic was an independent risk factor for late diagnosis. 
Devoting so much attention in the literature to late diagnosis and its 
avoidance may lead to the assumption that a low proportion of late-diagnosed 
cases is a favourable epidemic situation. However, in our data, the lowest 
proportions of late-diagnosed cases coincided quite naturally with the early 
phases of the spread of HIV to respective transmission groups. Illustratively, 
in the last four-year study period, the proportion of late diagnosis was 
highest (37%) in the rapidly contained outbreak among IDUs, and lowest 
(19%) in the MSM sub-epidemic characterised by a rising incidence. A low 
proportion of late-diagnosed cases can be a desired outcome of prevention 
and testing policies, but combined with rising HIV incidence, may also 
signal new transmissions.
6.5. Strengths and limitations (I-IV)
This study has several advantages. The study population covers a large 
majority of the whole HIV outbreak among Finnish IDUs and is the first 
study to describe the spatial spread and containment of an IDU outbreak over 
time. It also includes data on all newly diagnosed HIV cases in the HUCH 
area, representing 65% of all HIV cases in Finland. The study period, which 
included the early stages of all sub-epidemics, enabled recognition of the 
stage of the epidemic as a risk factor for late HIV diagnosis. In addition, the 
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virological sub-study contributes data to the debate on clinical differences 
between the HIV subtypes, and suggests the possible role of this recombinant 
subtype in the rapid spread of the IDU outbreak.
This study nevertheless has limitations that must be considered. Firstly, 
this study covers only some of the wide range of factors that influence the 
spread of HIV, whereas many known and unknown factors remain beyond 
its scope. Thus, the results can neither to prove the effects of different factors 
or interventions nor to weigh their impact against the spread of HIV.
In addition, the individual sub-studies have their limitations. The 
different quantitation assays used in the comparison of the two subtypes 
are discussed here earlier. Regarding the study on sexual behaviour, the 
small sample size, the missing data regarding HIV status of one’s partners 
and the different selection criteria of the two study populations limit the 
conclusions. In the study on the spatial spread of HIV, data on the spatial 
distribution of HIV-negative IDUs and data on networking between HIV-
positive and HIV-negative IDUs would have added much to the analysis. 
In addition, the inclusion criteria vary between the sub-studies, and may 
limit the generalisation of the results. Finally, the reason for HIV testing 
was recorded only for IDUs, not for all newly diagnosed cases in the study 
that described trends in late HIV diagnosis.
6.6. Implications  (I-IV)            
This study demonstrates the importance of outreach work and other 
preventive efforts that target the hard-to-reach population of marginalised 
IDUs. The HIV outbreak occurred in socioeconomically defined areas, which 
– except for the city centre – were characterised by high unemployment 
rates and low income (i.e. the most deprived neighborhoods in the Helsinki 
region). 
Friedman et al. described in 1995 that in low prevalence countries, HIV 
may be concentrated in socio-behavioural pockets of infection. The present 
study shows that these social pockets are located in pockets of poverty 
within the region. To prevent outbreaks, these pockets must be identified 
and reached, ideally before the spread of HIV. In addition to outreach and 
other peer work, this may include the decentralisation of NEP and of other 
services, and collaboration between the health care and the local social 
sector.
These results can be generalised to similar countries and areas with low-
level epidemics, and to some extent to other concentrated IDU epidemics 
as well. Studies show that large geographical differences in prevalence of 
HIV also exist in those countries where HIV is highly concentrated among 
IDUs. In high prevalence settings, far more resources are clearly needed to 
curb the outbreak. However, to identify and to reach marginalised IDUs in 
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deprived neighborhoods is an important challenge in all settings. 
The second implication of this study is the prevention targeted at the 
sexual behaviour of IDUs. Inconsistent condom use is common among 
HIV-positive and HIV-negative IDUs, and was associated with steady 
relationships and with recent addiction care. This creates a risk for HIV 
spread, but also highlights opportunities for prevention. A large majority of 
IDUs had previously used addiction care services, which suggests combining 
HIV prevention with these services. 
Although many studies report the difficulty in changing sexual behaviour, 
behavioural interventions are shown to be effective, especially when they 
include certain behavioural skills components.194 Behavioural interventions 
may also be easier when combined with addiction care than with NEPs, 
since such interventions require several sessions, and when in treatment, 
IDUs are likely to be off drugs and more receptive to the interventions. 
However, interventions are also needed to facilitate safer sex among out-of-
treatment IDUs. Since unprotected sex was unassociated with markers of 
marginalisation, commercial sex or gender, the results underscore the need 
to target the interventions structured for every IDU. Furthermore, the steady 
partners of IDUs should be actively offered intervention and HIV testing. 
Thirdly, to facilitate early HIV diagnosis, this study suggests increasing 
of HIV testing. An increase in routine HIV testing actively offered as a part 
of health care, and new low-threshold testing opportunities are needed, 
especially for heterosexuals who are often diagnosed late. For MSM, this 
study also suggests strengthening primary prevention measures because of 
increasing HIV incidence despite increases in previously tested cases. 
Public awareness of HIV, of promising prognoses and the importance 
of early diagnosis should be raised, as should such awareness among 
physicians and other health care personnel. Anonymous, low-threshold 
HIV testing should be easily available in all health care settings. In addition, 
it is important to continue and to develop alternative testing possibilities, 
such as through NGOs.
Despite these needs to develop and increase HIV testing in Finland, 
this study does not support the view that late diagnosis would be more 
common in countries with low-level HIV epidemics, which is an important 
background for new testing policies. Lower proportions of late diagnosed 
cases are reported only from Australia, another country with a low-level 
epidemic.83
Finally, there are some lessons learned regarding HIV surveillance and 
similar studies. Including baseline CD4 data in HIV surveillance has been 
recommended and has begun in 26 countries in Europe, and a common 
definition for late diagnosis is under discussion.265 This study shows that local 
data on the epidemiology of late HIV diagnosis is valuable, since trends and 
risk factors vary between countries and studies. The 20-year study period 
also shows that the proportion of late-diagnosed cases reflects not only 
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the problem of late HIV testing, but also the stage of the local epidemic. 
The stage and the age of the epidemic must be taken into account when 
interpreting surveillance data and studies on late HIV diagnosis, especially 
in cross-country comparisons. The goal must be early diagnosis rather than 
a low proportion of late diagnoses.
6.7. Future considerations 
In the future, monitoring the baseline CD4 cell counts of the national HIV 
surveillance data makes it possible to recognise groups at risk for late diagnosis 
in Finland, and shows in which geographical areas and transmission groups 
HIV testing must be improved. In order to recognise recent infections and 
thus groups and areas that require targeted prevention programmes, baseline 
CD4 cell count data on newly diagnosed HIV cases can be complemented 
with serological tests that recognise recent HIV infections (STARHS).
According to a comment by Wilson and Halperin published in the August 
2008 issue of The Lancet, the key research question in concentrated epidemics 
is “How to reach vulnerable groups with high coverage of high-quality 
targeted interventions?”.266 This study provides some answers, though leaving 
many questions unanswered. To know more about the spatial distribution of 
HIV-negative IDUs in Finland, about the mobility, characteristics, behaviour 
and networking between different sub-populations of IDUs, as well as to 
obtain more qualitative information about the risky sexual behaviour of IDUs 
would be important. Furthermore, the sexual partners of IDUs as a high-risk 
group for HIV should also be included in studies and interventions.
Moreover, IDUs are only one of the vulnerable groups. Study IV shows 
the growing number of newly acquired HIV infections among MSM, and the 
relatively large number of immigrants among heterosexual transmissions, 
both groups at risk for late diagnosis. At the same time, one in three 
HIV infections among Finnish heterosexual males – excluded from the 
“vulnerable groups” – is diagnosed too late, reflecting the paradox that 
those with no perceived risk are at greater risk for late diagnosis.120 In low-
prevalence countries, it is thus important not only to target high-risk areas 
and populations early with interventions and research, but to expand low-




Shortly after HIV-1 infection, Finnish IDUs infected with I. 
the recombinant subtype CRF01_AEFin had higher viral 
loads than did the Amsterdam IDUs infected with subtype 
B. This higher viral load may have contributed to the rapid 
spread of the outbreak.
The Finnish HIV outbreak was socially restricted to a II. 
marginalised IDU population, and spatially to local pockets of 
poverty. To prevent HIV among IDUs, these pockets should be 
identified and reached early through outreach work and through 
the decentralisation of NEPs and other prevention activities. 
Unprotected sex is common among both HIV-positive and HIV-III. 
negative IDUs, and enables HIV and other sexually transmitted 
infections to spread among Finnish IDUs. Inconsistent condom 
use is common in steady relationships, and is related to recent 
addiction treatment. Since the majority of IDUs receive addic-
tion treatment services, this provides an important opportunity 
to reach IDUs for HIV prevention, which should also focus on 
sexual behaviour. Developing a structure and opportunities for 
testing the partners of IDUs may play an important role in the 
early diagnosis of new HIV transmissions. 
The proportion of late-diagnosed cases varies between the sub-IV. 
epidemics and time-periods, and reflects not only the continu-
ing problem of delayed HIV testing, but also the dynamics of 
sub-epidemics. IDUs are diagnosed as HIV-positive earlier than 
are other transmission groups, but are at greater risk for entering 
care late. The low proportion of late-diagnosed cases and the high 
median CD4 level in the early years of each sub-epidemic suggest 
that sexual epidemics were also detected early, which may have 
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